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In July 2021 1339 drug related deaths (DRDs) were recorded in Scotland for the year 2020, the 
highest number on record.  To put this in context, National Records of Scotland estimate this figure 
to be three times that of the UK1. To reduce DRDs and other harms associated with drug use, 
Medication Assisted Treatment (MAT) Standards for Scotland were published in May 2021, with 
the aim to deliver and measure a no barrier, consistent access to treatment regardless of individual 
circumstances and ensure appropriate choice re medications prescribed, deliver assertive outreach 
to those not in services and ensure people are retained on MAT for as long as they need it. This 
project sought to provide a baseline of current MAT provision, prior to implementation, from the 
perspective of people currently in treatment. It is intended to be a reference point to inform and 
improve practice in relation to implementation of MAT. 
Methods
A semi-structured questionnaire was used in which telephone interviews collected both quantitative 
and qualitative data from participants. Data collection was facilitated by 13 peer researchers, 6 of the 
core group of interviewers were still in treatment themselves. The study aimed to recruit a sample 
of 20 participants from each of the targeted areas: Ayrshire and Arran, Grampian, Greater Glasgow 
and Clyde, Lanarkshire, Lothian, and Tayside. The project was approved by NHS clinical governance 
teams in each of the health board areas. A multi-faceted recruitment process was used to ensure 
as representative a sample, as possible, under the constraints of Covid 19. Due to the challenges of 
recruitment, in a pandemic, 95 people in total took part in the study. Qualitative questions provided 
in depth insights into the experience of people accessing MAT across Scotland. 
A sample of 16 participants from Perth Prison were also included in this study. This was analysed 
separately and included as an appendix.
Quantitative findings
Data was collected from 95 participants, 53 male, 41 female and 1 preferring not to say. Participants 
were between 24 and 64 years old with, 53%* of participants were in the 35-44 years old age bracket. 
Key findings were:
	59% were living alone
	6% had children under 18 years of age living with them, all females
	44% were living in a range of temporary accommodation settings
	97% were currently in treatment
	Currently prescribed medication for MAT: 61% methadone; 12% buprenorphine wafer; 9% 
buprenorphine sublingual tablets; 9% long-acting buprenorphine injection; 9%*other
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Standard 1 – Same day prescribing
	8% had access to same day prescribing
	86% feel the process of starting MAT could be improved
Standard 2 – Choice
	58% stated prescribing option were discussed; of this figure 71% felt they had enough 
information to make an informed choice
	62% stated medication dose was discussed; of this figure 56% felt it was a shared decision
	52% were daily supervised pre-March 2020 lockdown; 27% daily supervised during first 
lockdown of March – June 2020; 47% currently daily dispensed
	55% would like a change to their current dispensing arrangements
Standard 5 – Retention
	92% had a current length of time in treatment of less than two years
	For 15%, this was their first and only experience of treatment 
	76% had a time when they needed extra support
	56% had a time when they felt at risk of dropping out of service
For the 85% who had previous experience of treatment: 
	39% had been retained in service for more than 3 years at some point
	For 33% the longest time ever retained in treatment is less than two years
	21% had two previous episodes in treatment
	64% experienced multiple episodes of three or more periods in treatment
*Percentages have been rounded to the nearest whole number which may result in total adding more to 100% 
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Additionally:
	76% felt physically safe to engage with services
	63% feel supported by their addiction worker
	47% feel supported by their prescriber
	64% feel supported by their pharmacist
Qualitative findings
Thematic analysis was undertaken on all 95 participant interviews. Key findings were:
	For people who had a history of engaging with treatment they feel that access has improved 
as waiting times have reduced. However, it is felt that this reduction from months to weeks 
is still too long.
	Limited access to diazepam detox or maintenance prescription.
	Contrasting picture emerged of people who feel it takes too long to get a therapeutic dose 
with others who feel their dose was too high for them.
	Some participants reported feeling there is more choice of medication available, however it 
is not felt decisions around choice and dose are always shared decisions between the person 
and the prescriber.
	Lack of consistency both, in and across, health board areas on choice of medication and dose.
	Staff taking time to explain and encourage discussion around dose and choice of medication 
promoted engagement, increased wellbeing, and satisfaction with treatment.
	For people who felt they had no choice of prescribing options, they expressed dissatisfaction 
with services.
	Majority of participants have little engagement with their prescriber or have opportunities to 
review medication. Significant number of participants do not know who their prescriber is.
	Participants have acknowledged that the pandemic has been challenging time for services 
however communication and change of staffing have been identified as areas for improvement.
	Majority of participants feel they need additional support with their mental health.
	Several participants have expressed that there are times they feel at risk of dropping out of 
service but the “safety net” of having access to a prescription keeps them in treatment.
	Feeling physically safe to access addiction services did not equate with people feeling 
emotionally safe; fear of perceived and actual punitive measure are impacting on ability of 
people to engage.
	Access to treatment was viewed as the most important component of harm reduction for 




This baseline evaluation of people’s experiences of accessing MAT in Scotland indicates why the 
implementation of the MAT standards are crucial to how people access and experience MAT across 
Scotland. The experiential narrative gives insight into ways in which action can reduce both drug related 
harms and drug related deaths by increasing satisfaction with services with same day prescribing, 
choice of treatment and subsequent retention. This snapshot illustrates the issues faced by people 
who are not retained in services long enough to access support needed to address presenting issues. 
It highlights that retention is a major issue and reinforces other studies SDF have undertaken. This 
work was intended to shed light on the current living experience of people using services and in 
doing so provide an overall picture to inform quality improvement at local and national levels. The 
findings outline the challenge is in the how to move from where we are, to where the MAT standards 
require services to be. This report suggests further work on implementation should consider actions 
in the following areas as both specific challenges and opportunities for improvement.
Access
Service models need to reflect the reality of the living situation of the people they are trying to 
reach. Isolation, social deprivation, and transient populations require services to meet them where 
they are at. Low threshold services which acknowledge and respond directly to these barriers need 
to be a first step.
Same day prescribing is essential, delivery models which facilitate this should be replicated and 
adapted to suit local circumstances. Faster processes for restarting MAT need to be developed to 
reduce disruption to MAT and deliver same day restarts.
Given the role of illicit benzodiazepine use in participants ability to engage with OST, increasing 
access to benzodiazepine detox and provision of maintenance prescriptions as a component of MAT 
should be available where required and clinically appropriate.
Choice
For people using services, seeing change is crucial. Autonomy and choice in making treatment 
decisions need to be at the heart of service improvement. Providing adequate information on 
options of medication and dose is necessary to empower people to have meaningful input in their 
care. Equitable access to a range of treatment options, in and across health boards, in order that 
choice of intervention is supported regardless of location. To address treatment holistically and 
taking account of barriers such as poor mental health, treatment support should include access to a 
range of psychosocial supports.
Support
COVID-19 has shown, in some areas, that service can be improved by creatively engaging people. 
Providing support which recognise the importance of connection within all aspects of care is key to 
providing emotionally safe environments for people to engage without fear of punitive responses. 
People need to feel listened to and able to discuss their life without fear; some aspects of current 
service design precludes engagement for some people. Responding in ways to develop trust is critical 
for all groups but especially important for females with children. Ways to establish and maintain 
meaningful therapeutic relationships should underpin all that services do. There is an opportunity 
for therapeutic relationships to develop across the wider system of care and it is key that staff in roles 
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with less focus on the therapeutic alliance such as pharmacy recognise the importance of their care 
and support in treatment retention. The gaps in access to additional support, in particular to mental 
health supports are evident. Services should proactively offer additional support at regular intervals 
to prevent missed opportunity for engagement and to review treatment goals. Treatment pathways 
between substance use and mental health services should be further developed to reflect the reality 
of people who have comorbid substance use and mental health problems and are accessing MAT.
Across the themes of access, choice and support, practice which is identified as disrupting delivery 
of MAT need to be eliminated if the MAT standards are to mark a watershed moment in reducing 
drug related harms and drug related deaths in Scotland.
Considerations for practice
The findings from this evaluation of people’s experiences of accessing MAT, suggest a number of 
considerations for practice as services progress with implementation of the MAT standards. These 
are outlined below.
Access
	Addressing barriers to access: Physically taking services, by increasing assertive outreach 
models to the most deprived areas will allow people the chance to talk and be listened 
to. This is a crucial first step to getting people into treatment by allowing opportunities to 
counteract their experience of endemic isolation.
	Same day prescribing: It is key that staff across all sectors take responsibility for raising 
expectations of faster access to treatment crucially, access to same day prescribing needs to 
mean same day. By informing people of the process of starting MAT expectations of receiving 
treatment upon your first contact with the service will create a cultural shift away from low 
expectations within this population.
	Harm reduction: Services should explore meaningful initiatives and new strategies to engage 
people receiving MAT in wider harm reduction advice and support in order to increase uptake 
and provide support to people most likely to benefit from this. The Glasgow City Council 
WAND initiative (Wound Care, Assessment of Injecting Risk, Naloxone and Dry Bloodspot 
testing) is one such example of an approach using a contingency management model to 
reduce harm amongst people who inject drugs18.
Choice
	Offering choice and involvement in care planning: Care planning needs to be a collaborative 
process, with timely, regular reviews. The role of the prescriber must be clarified to ensure 
adequate opportunities to discuss medication choice and dose and allow immediate changes 
to medication if required. In particular this means that all people using MAT should know 
who their prescriber is. Conversations should also include exploring and reviewing dispensing 
arrangements such as opportunities for take home prescriptions.
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	Training, information and communication: Staff across sectors should have access to up-to-
date information and training on MAT treatment options in order to be able to effectively 
inform their service users. Services should consider different mediums of sharing information 
with service users which support in person communication, this could include leaflets or 
digital resources.
Support
	Developing support pathways: Service delivery should ensure that the experience of people 
using services is taken into consideration to develop support pathways that currently do not 
exist for them to access the right level of support, at the right time, and by the right people. 
Particular attention to addressing the pathway into mental health support should be given 
to avoid people falling through the gaps of being unable to fully engage in MAT due to their 
mental health, yet unable to access adequate mental health support when in receipt of MAT.
	Developing therapeutic relationships: It is crucial to recognise the importance of connection 
in developing therapeutic relationships between staff and people accessing treatment and 
equally important staff need to be willing to review this when people in treatment feel, for 
whatever reason, that a connection is not there. Continuity of support, including changes to 
named workers should be minimised to allow development of therapeutic alliances with key 
staff. Staff within the wider system of care such as pharmacy staff, have a key role to play in 
developing therapeutic relationships and should aim to strengthen these engagements, no 
matter how brief, ultimately helping to retain people in treatment.
	Challenging stigma: To change the experience of stigma for people using services, the 
workforce training and development needs to lead to a culture change which is more trauma 
informed in order for people to feel emotionally safe to disclose their needs and barriers 
which may affect their engagement without fear of sanctions or the removal of services. This 
is particularly an issue for woman with children who wish to access services and have a strong 
fear of losing custody of children. Targeted supports which take account of the particular 
needs of women would be beneficial.
11
Acknowledgements
This work would have not been possible without the sheer tenacity and commitment of our peer 
researchers in all aspects of this study. Special thanks to Barry, James, Joanne, Kevin, Lee, Maureen, 
Michelle, Rachel, Ryan, Sara, Scott, Steven, and Sylvia.
Thank you to the Drug Death Task Force and the Medication Assisted Treatment Implementation 
and Support Team (MIST) for supporting this work.
Thanks to Dr Karen Matthews, School of Health Science, Queen Margaret University, Edinburgh for 
providing external validation and project support.
Thank you to all services who helped to identify participants and raise awareness of the study across 
the 6 health board areas. 
Finally, thank you to all participants who willingly gave their time and engaged so fully with the work 
despite a global pandemic. The study team wish you all the very best for the future.
12
Background
In July 2021 1339 drug related deaths (DRDs) were recorded for the fifth year in a row. To put this 
in wider context, National Records of Scotland estimate this figure to be 3.5 times that of the UK1.
Continuing the emphasis of the Scottish Government Drug and Alcohol Strategy, ‘Rights, Respect 
and Recovery3 of evidence-informed interventions to Scotland’s drug problems, Medication Assisted 
Treatment (MAT) Standards for Scotland: access, choice and support were published on 31st May 
20214. Alongside the Scottish Government Health and Social Care Standards: my support, my life5, 
there is a clear policy directive and framework to deliver evidence-informed interventions which put 
people receiving care and support at the centre of decisions made about their care and how it will 
be delivered.
The MAT standards aim to deliver and measure a consistent no barrier access to treatment in 
Scotland regardless of individual circumstances. They are clear on what people should expect from 
services with the aim to reduce DRD’s and other harms associated with drug use. This study sought 
to provide a baseline of current MAT provision, prior to implementation, from the perspective of 
people currently in treatment. It is intended to be a reference point to inform and improve practice 
in relation to MAT. 
Aims
Overall Aim
The aim of the evaluation was to provide a baseline of current practice in 6 health board areas across 
Scotland of medication assisted treatment.
Survey Questions
To establish individual experience of MAT the themes of access, choice and support were explored in 
a semi structured questionnaire collecting both quantitative and qualitative data from participants. 
Question and prompts were based on the first five proposed standards for implementation, which 




 All people accessing services have the option to start MAT from the same day of   
 presentation.
 Standard 2
 All people are supported to make an informed choice on what medication to use for MAT  
 and the appropriate dose.
 Standards 3
 All people at high risk of drug- related harm are proactively identified and offered support  
 to commence, re-commence or continue MAT.
 Standard 4
 All people are offered evidence-based harm reduction at the point of MAT delivery.
 Standard 5
 All people will receive support to remain in treatment as long as requested.
The study covered themes of:
	Previous experience of MAT
	Current experience of MAT
	Access to MAT
	Choice of medication, dose, and dispensing arrangements
	Support and retention in services
The questionnaire was designed to facilitate discussion around aspects of access, choice and support 
which made a key difference to participants rather than attempt to quantify ever possible intervention 
on offer in each of the 6 health board areas. 
In line with the standards, the term Medication Assisted Treatment (MAT) is used in this report to refer 
to, “the use of medication such as opioids, together with any psychological and social support, in the 




Scottish Drugs Forum (SDF) Peer Research Model
SDF has over twenty-years’ experience in successful delivery of peer research projects across 
Scotland, this method was applied to this study. 
Seventeen existing and newly recruited SDF volunteers completed training on the MAT study. 
Peers were involved in all aspects of planning and delivery of this work. Peer researchers recruited 
participants through their own peer networks to pilot the questionnaire. From this one participant, 
who took part in the pilot, was recruited as an SDF peer, and conducted interviews themselves in 
the study.
A core of eight volunteers carried out most of the interviews. Six of this core group were still receiving 
MAT themselves throughout the project timeframe. Participants were made aware that all peer 
researchers had experienced treatment services to encourage engagement and elicit a more honest 
response.
Due to ongoing Covid 19 restrictions all interviews were conducted via the telephone between 
participant and peer researcher with a SDF User Involvement Officer (UIDO) on the line recording a 
verbatim written transcript of participant responses. 
Sampling and recruitment
Participants were recruited from 6 health board areas recording some of the highest incidences of 
drug related deaths based on annual averages from 2014 -2018 1. Consideration was also given to 
ensure the study reflected a geographical spread across Scotland with representation from both 
urban and rural settings. To this end the study aimed to recruit a sample of 20 participants from 
Ayrshire and Arran, Grampian, Greater Glasgow and Clyde, Lanarkshire, Lothian, and Tayside to 
achieve this balance. The project was approved by NHS Clinical Governance teams in each of the 
health board areas.
Twenty-one Alcohol and Drug Partnerships (ADPs), NHS addiction services and third sector services 
within the target health board areas, were informed directly of the study. Wider publicity for the 
study was shared more extensively through SDF social media platforms and a targeted approach to 
delegates, who attended MAT implementation workshops hosted by SDF, was applied.  Hard copies 
of recruitment flyers (appendix 1) were circulated where Covid 19 restrictions permitted. Peer 
researchers disseminated study information through their own networks. 
On invitation, Teams and Zoom meetings were arranged with ADPs, frontline services, and key staff 
members to facilitate support and recruitment for the study by SDF’s UIDO.
A sample of 95 participants were interviewed across the 6 health board areas, falling short of 
anticipated 120 target.  All health boards areas were represented in the sample covering 14 local 
authority area postcodes. 
Inclusion criteria were to recruit participants who had engaged for the first time or re-engaged with 
MAT over the past 18 months and currently in treatment.
Exclusion criteria was for anyone not currently starting or re-starting MAT over the last 18 months 
and under 18 years of age in receipt of MAT. 
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An additional 16 participants were interviewed in Perth Prison. This was analysed separately and 
included as an appendix (see appendix 2).
Data Collection Tool
A semi structured questionnaire was co-produced by members of the Scottish Government Drug 
Death Task Force MAT subgroup and peer research volunteers at Scottish Drugs Forum. Semi 
structured interviews collected both qualitative and quantitative data from participants.
The themes in the questionnaire and prompts were based on the first 5 proposed MAT standards.  
The questionnaire was piloted in two of the 6 health board areas and minor revisions were made. 
The pilot responses are included in the findings. Interviews lasted on average 40-45 minutes. The 
questionnaire and prompt guide are attached (see appendix 3).
Data Collection Process
A first name and contact phone number were forwarded by service providers or via peer 
researchers to SDF’s UIDO. Some potential participants contacted the SDF directly after being 
handed a flyer or in response to a social media post. A participant information sheet (see appendix 
4) was texted to those wishing to take part. UIDO then made contact to ensure that individuals 
met the inclusion criteria and were given the opportunity to ask any questions they had and to 
give verbal consent to take part in the study.   A follow up call was arranged. In line with good 
practice ethical guidance, participants were informed that they could withdraw from the study 
at any time. No participants chose to do this, although a few participants were given a break as 
they became upset and teary describing some aspects of their treatment and upon disclosure of 
traumatic life events. Participants were signposted to services, as necessary. One interview was 
terminated by SDF’s UIDO as participant was under the influence, SDF’s ‘What to do if’ protocol 
was followed on this occasion and support given to participant (appendix 5).
After each interview, the UIDO and peer researcher had a debrief of the interview and checked 
transcript for accuracy. Regular peer researcher meetings were held, throughout the data collection 
period, to give support and opportunity to identify emerging themes.
Data collection period was from December 2020 and initially planned to end 31st March 2021. The 
data collection period was extended to include the prison cohort and to maximise opportunities 
for community participation due to challenges of remote recruitment during the pandemic. Data 
collection period ended on 7th May 2021.
Participants were given the option of a £10 e-voucher or a postal voucher, based on preference 
and access to a smart device, most participants chose an e-voucher. This was as an honorarium 
for participation.
In addition, participants were encouraged to help recruit further individuals to the study and 
were given a further £10 supermarket voucher, as an honorarium, for recruiting people from their 
networks who met the criteria. This additional voucher was only distributed after completion of 
the interview. Twenty participants were recruited this way.
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Individuals who wished to take part but did not meet the criteria were signposted on to other SDF 
studies as appropriate: Experience of Stigma in East Ayrshire Services6; Hepatitis Scotland, HCV 
completed treatment survey peer research scoping exercise and Injecting Equipment Provision 
peer research scoping exercise. Additionally, 8%* participants (n=8) were identified as appropriate 
for the MAT study from these SDF studies and agreed for the contact details to be passed on.
Data Management and Analysis 
Qualitative data was entered into NVivo database for storage and analysis. Additionally, Survey 
Monkey (Team Advantage Package) and Excel were used to double check individual transcripts 
as well as to analyse quantitative data.  All individual transcripts were sent electronically to Dr 
Karen Matthews Queen Margaret University, Edinburgh in PDF, Excel, and SPSS formats to provide 
external validation and project support. Data was shared with internal SDF steering group for 
this project.  A thematic analysis approach was used in which themes emerging under each of 
underpinning areas of the MAT standards; access, choice and support were identified and the 
range of experience under each theme presented using verbatim quotes. Thematic analysis was 
undertaken on all 95 community and 16 prison interviews. 
Topics most relevant to the standards form this report. Outstanding information gathered will be 
used to inform future work on the MAT standards.
Individual health board areas will not be identified in the report.
Strengths and Limitations of the Study
The study sought to recruit 120 individuals across 6 health board areas who had started or re-
engaged with treatment services over the past 18 months for MAT. 
A limitation is the possibility that the sample could have been more representative of people in 
treatment. Engagement from services was lower than anticipated or experienced by other SDF 
studies during the pandemic. Recruitment relied on a few key individuals within each health board 
area as well as peer networks. As such this was a self-selecting sample as the onus was on individual 
workers and potential participants to consent to their information to be passed on or to make direct 
contact with SDF. This was anticipated and every effort was made to promote this study across a 
range of sites and peer networks to reduce bias in the sample. A further possible limitation was that 
participants required access to a telephone which had the potential to exclude some people from 
this study. 
A strength of the research was when contact with participants was made, individuals were very 
engaged in the process. Some participants stated to prefer the anonymity of the telephone interview 
as they felt more comfortable engaging outside a service setting. Additionally, some participants 
commented that a telephone interview reduced anxiety of talking about their experience of 
treatment and stated they may not have taken part in a community setting. 
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Feedback from participants on the study include:
“This is the first time that I have felt listened to”.
        “You can’t learn this from a textbook, I can only be honest with people who know what it is 
like”.
Additionally, 9 % (n= 9) of the study participants enquired about volunteer opportunity with SDF. 
Testament to the strength of the peer research model is that it indirectly promotes volunteering 
opportunities to people who may benefit from it beyond the scope of the study as well as being a 
conduit to meaningful engagement.
To gain information around current access to treatment the inclusion criteria of starting treatment 
within 18 months was decided by the project team to ensure as up to date an insight into current 
service provision as possible. However, due to the challenges of recruitment in a global pandemic, 
this criteria were relaxed to include 15 participants who were in service for two years. 
A strength of this data is that it can be used as a further resource to assist with the implementation 
of the MAT standards.




Telephone interviews were conducted over a 6-month data collection period ,95 people participated. 
In terms of gender, 53 respondents identified as male, 41 identified as female and 1 participant 
preferred not to disclose. The most common (mode) age of participants was in the 35-44 years old 
age bracket 53% (n=50). Table 1 displays the age categories of participants.
Table 1: Age Categories of participants
Age Categories N %
24-34 years 24 25
35-44 years 50 53
45-54 years 15 16
55-64 years 5 5
Missing 1 1
Total 95 100*
*Percentages have been rounded to the nearest whole number which may result in total adding to more than 100%
Interviews covered 6 health board areas Ayrshire and Arran, Grampian, Greater Glasgow and Clyde, 
Lanarkshire, Lothian, and Tayside, representing 21 Alcohol and Drug Partnership (ADP) areas. Within 
this sample, 14 local authority areas were represented covering rural and urban locations.
Demographic Profile of Participants
All participants were white with 91 %* (n= 86) describing themselves as Scottish, 6% (n=6) British and 
3% (n= 3) English. Over half of the sample have their own tenancy via council, housing associations 
or private let 61% (n=58). Of this group 9% (n=5) preferred to stay somewhere other than their 
own tenancy. The remaining 44% (n=42) lived in a range of temporary settings. Details of living 
arrangements displayed in table 2.
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Table 2: Accommodation arrangements of participants
Accommodation Arrangements N %
Own Tenancy 50 53
5 have their own tenancy but stay 
somewhere else- 1 preferring 
to be street homeless/ 4 staying 
friends/family
5 5
Supported Accommodation 8 8
Temporary Homeless 15 16
Staying family 5 5
Staying with friends 4 4
Staying with partner 3 3
Between partner and mum 1 1
Street Homeless 1 1
Private Let 3 3
Total 95 99*
*Percentages have been rounded to the nearest whole number which may result in total adding to more than 100%
Participants were asked if they lived alone or if anyone else lived with them, 59% (n=56) responded 
that they lived alone as displayed in table 3 below.
Table 3: How many people live with you
How many people live with 
you?
N %




Greater than 5 6 6
Total 95 99*
Of the 95 responses, 94% (n=89) had no children under the age of 18 living with them. For the 6% 
(n=6) who had children living with them, all were female. Additionally, 7% (n=7) respondents have 
children under 18 years of age currently not living with them, this was slightly higher for female 
participants, 4% (n=4), than male respondents, 3% (n=3).
*Percentages have been rounded to the nearest whole number which may result in total adding more to 100%
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Current and previous experience of treatment
Participants were asked which medication they are currently prescribed for MAT. Table 4 displays 
participants current treatment that they are receiving, 97 % (n=92) of the sample were currently in 
treatment. Two participants are trying to re-engage with service for the second time in 18 months. 
One participant just finished treatment in the few days before their interview; they had started 
treatment within the last two years.






Buprenorphine wafer 11 12





Currently on no medication, 
waiting to start long-acting 
buprenorphine injection, 
hopefully within the next week
1 1
Currently on waiting list (no 
indication of timeframe given 
from service). Second time 
starting MAT in last 18-month 
period.
1 1
Currently trying to get into 
treatment, not on waiting list 
(street homeless). Second time 
starting MAT in last 18-month 
period.
1 1
Just finished treatment (Started 
MAT in last 2 years)
1 1
Total 95 99*
*Percentages have been rounded to the nearest whole number which may result in total adding to more than 100%
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Participants were then asked how long they have currently been in treatment. Responses are 
displayed in table 5.
 Table 5: Current length of time in treatment
Current length of time in 
treatment
N %
1 – 10 days 5 5
1 – 6 months 28 29
6-12 months 34 36
1-2 years 6 6
2 years 12 13
On and off for two years 2 2
3 years (both pilot interview) 2 2
More 5 years (pilot interview) 1 1
Five year in total but I had a 
break in between
1 1
Waiting list 2 2
Trying to access service 1 1
Finished treatment 1 1
Total 95 99*
*Percentages have been rounded to the nearest whole number which may result in total adding to more than 100%
Participants were asked the longest time that they have ever been in treatment and the number of 
times that they have started MAT. Table 6 displays these figures respectively as can be seen.
Table 6: Longest time consistently on MAT
Length of time consistently on 
MAT
N %
1-6 months 8 8
6-12 months 6 6
1-2 years 17 18
2-3 years 25 26
4-5 years 12 13
Over 5 years 12 13
Over 10 years 10 11
Off methadone 3 months ago to 
start long acting buprenorphine 
injection
1 1
Not sure 3 3
Missing 1 1
Total 95 100*
*Percentages have been rounded to the nearest whole number which may result in total adding to more than 100%
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Table 7: Number of times in treatment







More than 10 7 7
Total 95 99*
*Percentages have been rounded to the nearest whole number which may result in total adding to more than 100%




Length of time to start treatment
Participants were asked how long it took to start their treatment; the table below provides a 
breakdown of the length of time to start treatment for the study sample. 
Table 8: Details length of time to start treatment.
Length of time to start treatment N %
Same day 8 8
Days 17 18
Up to 2 weeks 15 16
Up to 1 month 30 32
2-3 months 13 14
4 months plus 6 6
Unsure 4 4
Waiting list 2 2
Total 95 100*
*Percentages have been rounded to the nearest whole number which may result in total adding to more than 100%
It was unclear whether the length of time to start treatment was from when individuals first contacted 
the service or from their first appointment. Participants referred to an assessment period, of varying 
lengths before starting treatment.
Same day prescribing
Same day prescribing was reported in four of the 6 health board areas indicating that same day 
prescribing is taking place. There was some evidence that same day prescribing was prioritised for 
more at-risk groups and for participants with children. Level of satisfaction was high for this group:
“put it this way, it’s the quickest. Someone made a call, and I got an appointment an hour later and 
started medication the next day.” (male, 45-54 years, 28 3/66)
“I got put on it the same day because I was fast tracked cause of the kids.” (female, 35 – 44 years, 
34 3/65)
Improved access
There was a general acknowledgement that waiting times have improved from, previous treatment 
episodes, with a few weeks wait perceived as good:
“It was quicker this time round, one or two weeks I think”. (male,35 -44 years, 27 3/68)
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For people who had a longer wait, it was still described as satisfactory although expectations around 
timeframe for access were low:
“I thought it would take longer but it only took 4 weeks, and I was surprised by how quick it was 
especially with Covid.” (male, 55-64 years, 38 3/72)
“6 weeks wait which isn’t too bad as I thought it would take longer.” (male, 35-44 years, 63 3/71)
For people who experienced a longer wait there was a narrative that this delay was caused by them 
rather than how the service is designed:
“I think I could maybe have got it quicker, but my drug use was erratic, and I was missing appointments” 
(female, 35-44 years, 65 3/69)
“I was too chaotic I had to wait 2/3 weeks”. (female, 35 -44 years, 8 3/74)
Several noted that their engagement was hindered due to withdrawals hampering their ability to 
engage at set times:
“Appointments when you are withdrawing are hard”. (female, 35- 44 years, 64 3/63)
“I am so ill with withdrawals that I can’t engage”. (female, 35-44 years, 70 3/28)
Waiting to start treatment
Frustration for people when waiting to start treatment was in the,’ not knowing how long they would 
have to wait’. The wait was described as a negative experience with continuing risk behaviours and 
isolation to manage the very issues which were factors in people seeking to access treatment in the 
first place. This is further confounded by some individuals describing a period of ambivalence before 
contacting the service:
“It took me a year to get the courage to go to the service but then things happened quite quickly, I 
was on a script within a week.” (male, 24-34 years, 3 3/10)
When further probed around, ‘what things were like for you while you waited?’, there was very 
limited support offered while people waited to start treatment:
“I wasn’t in my right mind so didn’t know where to get help (when I was waiting)”. (female, 35- 44 
years, 8 3/21)
“Timing is a big issue; no other support is offered while you wait.” (female, 35-44 years, 78 3/49)
One respondent reduced their drug use when waiting to start treatment. Over half the sample, 51% 
(n=48) explicitly reported drug use staying the same or increasing:
“If I had stopped using, I would have went into withdrawals and might not have made it into 
treatment.” (male, 24-34 years, 42 3/3)
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“The wait made things worse…. I didn’t want to keep using but I had to maintain my habit until I got 
into treatment.” (female,24-34 years, 92 3/4)
Poor mental health was acknowledged, in just under half 40%* (n=38) of responses, due to drug use, 
and associated lifestyle contributing to the need for referral to services. No responses indicated an 
improvement in managing mental health symptoms while waiting to start treatment:
“Jesus Christ my mental health was bad enough without all that crap of being chaotic and waiting on 
a script”. (female 24-34, years, 54 3/6)
“My mental health was terrible. I think if anything it probably got worse, things certainly didn’t 
improve when I was waiting. I hope people don’t die in between times when we are waiting on these 
MAT standards.” (male, 35- 44 years, 62 3/7)
Process of MAT
Table 9 displays responses to the question, ‘do you think the process of getting on MAT could be 
improved?’
Table 9: Process of MAT
Do you think the process 





No response 1 1
Total 95 100*
*Percentages have been rounded to the nearest whole number which may result in total adding to more than 100%
When asked, ‘if the process of starting MAT could be improved’, participants 86% (N= 82) felt 
there was room for improvement. There was a general acknowledgement that waiting times have 
improved however for some participants it was stated that, although things had improved for them, 
this was not necessarily the experience of their peers. Among respondents who had experienced 
faster access to treatment the perception was around their “luck” rather than access being hastened 
by clinical need or a general standard in the service.
“Taking away Covid, things have improved just by the speed that you get on it compared to years 
ago. I know I was lucky this time, I know plenty of people who had to wait 2/3 weeks to get on it”. 
This is too slow to prevent overdose and prevent people having a rough few weeks while they wait.” 
(male, 35 – 44 years, 7 3/40/55)
Window of opportunity
Participants linked delays in commencing treatment with missed opportunities to reduce risk and 
drug related deaths. This period was acknowledged as a crucial moment to engage with people 
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seeking treatment and the need for service to seize this as an opportune but limited window to start 
people on MAT. There was concern that any waiting time reduces the likelihood of people being able 
make it to start treatment. 
“Definitely, it takes too long, and the window of opportunity is small so services should be designed 
to capitalise on this.” (male, 24 – 34 years, 6 3/46)
“As you are still doing everything wrong while you wait, and you are wanting help, so it is really 
difficult. When you want help you need it there and then.” (female, 24-34 years, 11 3/47)
“The time you have to wait to start treatment should be cut. It is so long winded that you really have 
to go through the motions and the window of opportunity is so small.” (male, 35-44 years,3/48)
“I am hearing of guys going to the clinic and being told to come back in 2/3 weeks’ time. By that time, 
you are dead. Two weeks is a long time to an addict, it’s more like two years”. (male 45 – 54 years, 
93 3/52)
Although there was variation in the period of time taken for people to start MAT from initial contact 
with a service, this sample did not indicate any differential access across age and gender. In terms 
of setting and service, homeless settings in urban areas were viewed as providing faster access to 
treatment. However, there is a perception that regional variation exists:
“It probably comes down to what area of the country you are in. Different areas act differently. I was 
lucky, but this is not the general experience of people I know “. (male, 45-54 years. 28 3/59)
Accessing treatment
When participants reflected on starting treatment, this was viewed as a positive experience. Access 
started the process of stabilising drug use and increased their awareness of other support services 
who could assist them. Crucially, it was viewed as saving lives:
“As soon as I started treatment, things started to improve massively”. (male 35 -44 years, 82 3/27)
“I think the service is great when you get into them and that they save your life, it is just having to 
wait.” (female 35- 44 years, 15 3/16)
Harm reduction
For many participants access to treatment was viewed as the most important harm reduction 
intervention as they experienced a reduction of adverse outcomes across many aspect of the life, 
when engaged in MAT. However, some participants acknowledged that their treatment fell short of 
reducing harm:
“My meth isn’t enough and I am still using. They gave me harm reduction advice but at the end of 
the day I am still using”. (male, 35-44 years, 68 8/19)
The questionnaire did not contain a section on specific harm reduction interventions rather peers 
promoted participants with, ‘what is the best piece of harm reduction advice you have received’. 
A few responses stated that they felt knowledgeable about harm reduction but were reticent to 
further engagement around this preferring to talk about their experience of accessing medication:
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“I have had loads of harm reduction advice over the years” (male, 45-54 years, 56 8/5)
“I know all about that side of things (harm reduction). I am quite knowledgeable about all that kind 
of stuff” (male, 45-54 years, 28 8/4)
“They tried to give me harm reduction advice and I am not being big headed, but I know it all” 
(male,35 -44 years, 59 8/18)
One participant acknowledged the impact of Covid 19 on harm reduction services:
“Before Covid there was like a drop in and you could show your injection site to the harm reduction 
team.” (male, prefer not to say, 66 8/19)
Of the participants who engaged in conversation around harm reduction, Naloxone was mentioned 
by 43 %* (N=41). There were degrees of knowledge of Naloxone within this group with some having 
received full training; this was more likely for those who had experienced criminal justice services. 
Whereas others described feeling less confident around Naloxone administration: 
“I have the Naloxone spray. I keep it in the house at all times. I have not had any training on it or been 
told how to do it. At the start of lockdown, I got posted out a nasal spray and got a leaflet.” (female, 
35-44 years, 64 648/9)
“I have Naloxone, but I wouldn’t know how to use it. They just want you out the door. I might ask 
when I am able to sort myself out again”. (female, 35-44 years 70 8/11)
“I have had three Naloxone (kits), but I have not had much harm reduction advice about how I can 
keep myself safe”. (male, 24 – 34 years, 57 8/7)
For all participants, who had Naloxone, no one had administered it.
For some 19 % *(n=18) participants, lack of access to a benzodiazepine prescription impeded their 
ability to fully engage with services even after commencing opiate replacement therapy (ORT):
“Most of the time I feel I need extra support. A constant problem that I have is that I don’t have any 
help for my benzo use. It’s a personal issue but addition services need to deal with all addiction not 
just opiate use e.g., benzo use.” (female, 35-44 years, 60 8/18)
“I am trying to get a benzo script. I have been trying for about a month. All that happens with my 
benzo use is they tell me to cut it down, but I need more help than that”. (male, 35-44 years, 44 9/18)
One female participant, with children, acknowledged her reluctance to ask for support for her 
benzodiazepine use due to fear of the consequences in doing so:
“Right now, I have nothing to hide but cards on the table. I am using a very minimum amount of 
benzos. I buy someone else’s prescription, so they are not street benzo’s. If I told them this, then I 
would be scared that my kids would be removed and put into care.” (female, 35- 44 years, 89 8/16)
One participant below, commented how much his life has changed after starting a benzodiazepine 
prescription alongside opioid substitution therapy:
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“You take horrible decisions on Valium that you wouldn’t normally take e.g. I ended up on crack 
cocaine. Now I am on a Valium script I feel normal. For the first time, I can actually see the future 
(male, years 35- 44 years, 58 8/8)
Ability to access service
In terms of accessing services, a range of experiences were acknowledged by participants which 
suggest a lack of consistency in services provided at the right time, by the right people across the 6 
health boards. 
The sentiment for many participants was in their ability to identify themselves that they needed 
support with services missing opportunities for timely engagement as illustrated below:
“I have been at risk through my own stupidity as I didn’t reach out to anyone and would just stay in 
and suck it and see. I have just stopped my meth overnight in the past. I know there is people that 
you can phone but I struggle to reach out and to ask people for help when I need it. I just cut myself 
off.” (female, 35-44 years, 17 6/242).
“When I told them, I wanted to drop out they kinda blamed me for not opening up and I tried to 
explain to them that seeing lots of different workers doesn’t help you. You are scared to say anything 
in case it effects your script.” (male, 34-44 years, 50 6/244)
“That’s not down to the service that is down to me. Sometimes, I just can’t be arsed. My moods and 
that. My worker just tells me to take few days. I have a good relationship with my worker. Sometimes, 
I like to cut myself off from the world. What would help? Probably me just answering the phone to 
the worker but sometimes that is the hardest thing to do even though I know that would make me 
feel better. I sometimes just feel at risk of dropping out, but I don’t know what more they could do to 
help me.” (female, 35-44 years, 55 6/178)
One participant, who is currently on a waiting list to start treatment for the second time in a year 
commented:
“I have (been at risk of dropping out in the past). Right now, it would be good to have a weekly 
appointment. All you want is to know someone actually thinks about you.” (male, 24-34 years, 88 
6/241)
Two participants acknowledged the impact of having someone close to them dying of a drug related 
death. One spoke in terms of a DRD facilitating her self-referral to services. For both individuals there 
was no engagement from assertive outreach services to identify either individual as potentially in 
need of service; the former participant expressed her disappointment at this:                                                              
“My ex-partner had OD’d and died that is why I made a referral. I had to find the service, no one came 
looking for me even though my partner had died of a DRD.” (female, 24-34 years, 53 3/2)
For the other participant, the same circumstances led to a challenging period before contacting 
services:
“My sister OD’d and died, and you think that would wise you up, but I went the other way into chaos 
29
before I contacted services”. (male, 35-44 years, 2 3/1).
This theme of needing encouragement to access services was acknowledged by one participants 
who recognised the barriers that appointment-based systems can have on your ability to access 
services:
“I had an initial appointment before lockdown and that was it. There is a perception, amongst people 
who I know use the service, that if you don’t turn up for an appointment then that is it. When you are 
still using you need coaxing to cut down, you need encouragement, but you go to the back of the list 
if you keep using. They will withhold your medication if you miss an appointment, your pharmacist 
tells you that you need to make an appointment to continue”. (female, 24-34 years, 92 7/111)
There was a recurring narrative around appointment systems contributing to disruption in delivery 
of MAT:
“When you are caught up in the drug world appointments and drug diaries are impossible.” (female, 
35-44 years, 65 3/13) 
“Previously I have dropped out as I can’t hang about waiting on appointments and I tell them this.” 
(male, 45-54 years, 12 6/244)
Majority of participants expressed frustration with trying to contact a worker in service. One 
participant suggested a protocol in place would help:
“Don’t get me wrong, sometimes you can get reception staff to send an email, but you can’t just get 
help when you need it. Be so much easier if they had a protocol in place so you know how you can 
contact your worker”. (female, 35-44 years, 64 7/84)
 Missing chemist
Some participants described the impact of disruption to their MAT treatment after missing their 
medication for three days or more. One respondent, currently on the waiting list, to re start her MAT 
after missing the chemist, she stated:
“I wish the service would work more closely with the pharmacy and have better procedures in place 
for restarting medication after missing it for a few days.” (female, 45-54 years, 5 6/233)
Other participants, below, described their return to risk behaviours after their MAT was discontinued 
for missing the chemist:
“Using everything I could get my hands on as I was replacing 80ml of methadone (after missing the 
chemist for three days). I have been in treatment about 6 times, and I feel I always stumble as I miss 
the chemist and get struck off and then have to start again.” (female, 35-44 years,41 3/34)
Again, another participant commented:
“It was harder the times that my medication was stopped by the service for missing the chemist.” 
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(male 35-44 years, 19 3/33)
The two participants below describe a positive and negative experience of missing the chemist for 3 
days in a row and service response:
“If I don’t go to the chemist now my worker is at my door doing a welfare check.” (male, 24-34 years, 
4 6/223)
“My worker never contacts me when I miss the chemist and I get pissed off when no one contacts me 
as I feel that no one cares, and it is left for me to get back in touch”. (female, 35- 44 years, 41 6/234)
One participant, who had started treatment twice over the last year, acknowledged his rapid re-
engagement with services and factors which facilitated it:
“I was able to get back into service quickly as after the first-time last year my worker kept my case 
open, he hadn’t shut me down, so I was able to get back. My wait, both times, was largely positive. 
Both times I could get medication pretty quickly but that is not everyone’s experience and I know this 
from recovery networks…. Things have absolutely improved, my experience of being kept open is 
rare….My experience is that when you make an effort you get support off them.” (male, 34-4 years, 
76 6 /237)
Services during Covid 
Participants acknowledged reduced access to support from services since March 2020 with the onset 
of the global pandemic. Participants recognised that the pandemic has been a challenging time for 
services however communication, change of staffing have been identified as areas for improvement, 
with some participants expressing frustration at the reduced contact with services over the last year:
“Since March 2020 no one has contacted me at all. I get support from my advocacy worker but not 
from (names addiction service)”. (female, 35-44 years, 23 6/90)
“What engagement, I have had two phone calls since the start of lockdown?” (male, 45-54 years 93 
,6/92)
“I can’t engage right now. There is no one to speak to. There is no follow up information”. (male,24-
34 years, 88 7/74)
“I would like support as I feel my head is a mess, but I have not had a chance to speak to someone”. 
(male, 24-34 years, 73 6/239) 
“Cause of Covid, the service didn’t want to see you and I should have been able to get extra help 
because I was having a baby.” (female, 35-44 years, 25 6/131)
“Last year I spoke to my worker once over the space of a year and it wasn’t even for five minutes. I 
understand the way the world is but still feel it could have been a bit more supportive.” (female, 35-
44 years, 65 6/137)
One participant stated missed opportunity for observational assessments by services over the 
pandemic and the impact on retention in MAT:
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“Over the past year, I was on monthly appointments, so I never really got the chance to discuss this 
(thinking of dropping out of service) and they weren’t seeing me enough to notice changes in my 
appearance, how I was presenting. There shouldn’t be such a gap in appointments and your worker 
shouldn’t change so much”. (male, 45-54 years, 22 6/243)
One participant commented on the importance of having outreach services to facilitate access to 
services: 
“Not extra medical support but moral support, we all need to know that we are alright. I had a near 
fatal overdose at the start of last year and I was only using cause I felt rough not cause I wanted to 
use. The peer team came to me and linked me into service. The whole Covid thing, is no substitute for 
the face to face.” (male, 35-44 years, 6/238)
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Choice
Participants were asked about their prescribing options. Table 10 below quantifys the choice 
offered and subsequent table 11 expands on the first question, by quantifying the degree to which 
participants had enough information to make an informed choice.
Table 10: Prescribing options. 
Were prescribing options 





Not sure 2 2
Total 95 100*
*Percentages have been rounded to the nearest whole number which may result in total adding to more than 100%
Table 11: Making an informed decision.
If yes, do you feel you had 






*Percentages have been rounded to the nearest whole number which may result in total adding to more than 100%
Informed Choice
The outcome of having an informed choice of medication meant that some individuals chose a drug 
which they knew had worked for them in the past or conversely were opting to try something new 
based on prior experience. There was some variation about which drugs were available in and across 
different health board areas, choice was very service dependent. For participants who felt their 
decision was a joint one, content analysis indicate this to be an overwhelming positive experience 
and indicative of a cultural shift in services. It was acknowledged that different medications work for 
different people, and that this may change over time:
“It was a shared decision. My worker said that it is my care, and it is my choice and I know not 
everyone had this”. (female, 35-44 years, 8 4/93)
“Things are so much better than before, it used to be up to the doctor what you were entitled to.” 
(male, 35-44 years, 83 4/162)
A few respondents spoke about having no choice on clinical grounds, yet as this was explained to 
them by their worker, they felt it was a joint decision:
33
“I have mental health issues. They said Subutex wouldn’t work as I am emotionally instable, and they 
said the better option for me was methadone and I think they were right with that. I don’t think I 
was ready for that; I think I would have relapsed if I was on Subutex.” (female 24 -34 years, 47 4/145)
This group accepted that an informed choice, did not necessarily result in receiving your preferred 
choice of medication, and were satisfied with the joint decision-making process.
The other strong emerging theme was that discussion of prescribing options did not always lead to 
treatment decisions feeling informed:
“I am not sure how much of an informed decision it was. I was given some options, but I wouldn’t say 
it was explained in detail.” (female, 35-44 years 78 4/123)
“I think things were discussed with me, but I don’t know how much my opinion was taken into 
account.” (male, 35- 44 years ,13 4/139)
Additionally, a few respondents commented on poor physical and mental health as well as withdrawals 
impacting on informed consent:
“I wasn’t in a state to understand options.” (female, 55-64 years ,72 4/22)
Many participants were unable to describe when prompted, options to review choice of medication.
No choice of prescribing options 
For participants who stated they had no choice of prescribing options, the sentiment of their responses 
was viewed as negative in relation to their experience of treatment; they viewed themselves as 
passive recipients of their treatment:
“they told me what I was to go on, I don’t feel I was given a choice.” (male, 35-44 years, 48 4/111)
“it wasn’t a shared decision; it was their decision.” (male 45-54 years, 45 4/131)
“I wasn’t consulted about what the right medication would be for me. I was just told this was the 
substitute for heroin and everything would help”. (male, 24-34 years, 73 4/136)
Few respondents commented that choice was not an informed one due to not having received 
adequate information on all choices available:
“I wasn’t sure what would work best for me and that wasn’t discussed, it was more like what do you 
want?” (male, 35-44 years, 50 4/135)
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Dose
Table 12: Dose discussed.
Was dose discussed with you? N %
Yes 59 62
No 31 33
Not sure 5 5
Total 95 100*
*Percentages have been rounded to the nearest whole number which may result in total adding to more than 100%
Table 13: Dose shared decision.
If yes, do you feel that the 





Not sure 7 12
Total 59 100*
*Percentages have been rounded to the nearest whole number which may result in total adding to more than 100%
Shared decision
Shared decision making, over medication dose, was presented as a positive aspect of treatment 
for 56 % (N=33) of participants. Staff taking time to explain and encourage discussion around dose 
promoted engagement and increased wellbeing:
“I don’t have a bad thing to say about the service as they have been really great with me. They 
explained the dose, they have been good for me”. (male, 55-64 years, 38 5/5)
“I was told it was my body and it was up to me”. (female, 45-54 years, 81 8/50)
“I got a leaflet re dose and was kept informed of how I would be titrated and the reasons why 
decisions were made.” (male, 45-54 years, 36 5/9)
“The nurse said if I needed more, I was to come back, but I felt brand new. I felt that the dose was 
carried out in a safe way, everything was explained, and my blood pressure was checked. It was 
getting on it in the first place that was the problem.” (female, 45-54 years, 86 5/15)
Not shared decision
A contrasting picture emerged for remaining participants 65 % (N=62) who asserted that it takes 
too long to establish a therapeutic dose against others who feel their dose was too high for them. 
There seemed to be a lack of consistency in communication to participants around their titration 
dose, leading to a lack of agency over medication and dissatisfaction with their treatment. Few 
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respondents articulated the tension between a perception of service protecting themselves from a 
drug related death over person centred care.
“I know every drug workers nightmare is giving out medication and then someone dying, but I really 
feel that I could have been up more”. (male, 35 – 44 years, 63 5/25)
“I feel I am rattling at night and have asked for an increase but have been told that it is too risky to 
put me up in case I OD. I am still using heroin every couple of days.” (male, 35-44 years, 48 5/38)
“Dose wasn’t discussed I was told. It was basically, no you can’t get an increase and it took months 
to get the dose I am on now. They are frightened to increase you when they can’t see you and I was 
still using IV.” (female, 24- 34 years, 54 5/40)
“No, I was put on 35ml to begin with, but it didn’t even touch the side.” (female, 35- 44 years, 23 
5/54)
“Dose was discussed, they started me on 20ml and then I was put up. I have been on 115ml before. 
20ml doesn’t tickle my tonsils. I was still using on top but they would only put me up by 5 mls. Dose 
was explained and apparently you have to start on a small dose and work your way up.” (female, 35 
-44 years, 65 5/19)
Few spoke around the need to have a fuller explanation around decision making to feel confident 
with accepting clinical advice:
“I had to build up to the dose I am on now. They wanted me to start on a higher dose but I didn’t want 
to as I felt what I had was holding me. They explained why they wanted to do this and only when they 
explained was I certain about what was the right dose for me.” (male, 35 – 44 years 82 5/13)
“I think it was the right dose now but not at the start I didn’t.” (female, 45-54, 20 5/53)
 A few participants acknowledged holding back medication or disengaging with services when they 
felt that their dose was increased without their consent, even if it may have been in their best 
interest:
“They shouldn’t be able to control you life so much. I can’t remember about dose. I was just itching to 
get on it. They might have explained it, I wasn’t in a state to take it in.” (female, 24 -34 years, 26 5/16)
“My dose was increased and increased, it was never a shared decision.” (male, 35-44 years, 19 5/35)
“They want to put you up as high as possible to keep them safe, it isn’t about what you want.” (male, 
35-44 years, 14 5/50)
“They should listen to how medication is affecting your body before making decisions about putting 
it up or down.” (female, 35-44 years, 46 5/37)
It was suggested by a couple of participants that increase dose could put people at more risk if they 
are still using street drugs:
“Because you give dirty urines, I don’t believe that the answer is for your dose to go up and up. There 
should come a point when someone should be saying, ‘hang on meth is not stopping the using” 
(male, 35-44 years, 7 5/32)
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“When I was on methadone, my dose was discussed with me although it wasn’t right as I was still 
using on top” (male, 24-34 years, 85 5/44)
Information
Participants acknowledged that feeling more informed whether from previous treatment episodes 
or from researching options themselves, was an important aspect in their recovery and increased 
satisfaction with their treatment. This was a theme which respondents were particularly passionate 
about; being active recipient of care:
“I felt informed as I had knowledge in my head from previous times in treatment.” (male, 45-54 
years, 31 4/183)
“You feel better when you can manage yourself, you need to be able to make your own choices.” 
(female, 35-44 years, 75 4/175)
“I need to know how things are going to work. I am not sure everyone asks but I like to understand. I 
am not going to go blindly into something.” (female, 35-44 years, 8 4/180)
“I knew a lot about things from my own education. I don’t think they tell you enough about the 
neuroscience behind how your medication affects your brain. This is something that I would like to 
know more about.” (male, 24- 34 years, 6 4/178/179)
Dispensing 
Table 14 displays dispensing arrangements before and during Covid 19 and current dispensing 
arrangements.
Table 14: Dispensing arrangements
Dispensing arrangements Frequency N %
Before lockdown March 
2020
Daily supervised 









During lockdown March 
2020
Daily supervised 









Current Daily supervised 









*Percentages have been rounded to the nearest whole number which may result in total adding to more than 100%
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Participants were asked to state their dispensing arrangements before and during Covid 19 lockdown 
compared to their current arrangements. There is a caveat to these figures, not all the study sample 
were in treatment before March 2020, some individuals started and stopped treatment during 
lockdown only to subsequently re-engage. Additionally, the research design assumed that the 
lockdown of March 2020 was a one-off event whereas people were in and out of various restrictive 
measures depending on where they lived over the last year.  What can be inferred from this data, 
is a period at the onset of the pandemic in which dispensing arrangements changed; the need to 
control viral transmission of Covid 19 superseded normal dispensing arrangements. The following 
qualitative data explore some of the implications of this.
The majority of responses acknowledged they had choice over which chemist they went to but no 
say in how frequently they went. There was some anger from participants that change to frequency 
of dispensing arrangements was only made possible due to Covid 19:
“I was told to just go every day until they trust you, but it only happened (reduced frequency) because 
of Covid.” (female, 34 – 44 years, 23 3/206)
“I have been daily for years and it has taken some virus to come along and change that”. (male, 45-
54 years, 93, 2/27)
“Since lockdown cause I get a weekly script (now) I feel x100 better not having to go to town and be 
surrounded by the wrong people when you are weekly, you are not reminded of your drug history all 
the time. It gives you a positive mindset.” (female, 35-44 years, 64 2/21)
Few respondents stated that daily engagement with the pharmacy added routine and structure to 
their life:
“Going everyday means I get washed every day and have a purpose”. (male, 35 – 44 years, 27 2/2)
Additionally, a further few responses illustrated a protective factor in having daily contact:
“I am happy with the way things are just now as I am not 100% stable”. (female, 24- 34 years 47 2/3)
“Being on a daily supervised dose is their way of checking to see if I am out my nut and that actually 
makes me feel safe.” (female, 24-34 years, 54 3/227)
For many participants daily supervised dispensing or pick up was viewed as punitive treatment 
which reinforces stigma:
“I have spoken to my worker 2 or 3 times in the last year, there is no support, you have to do it 
yourself and then they punish you by having to go daily. It is a daily embarrassment.” (male, 35-44 
years, 19 7/77)
Comments from some of the participants illustrate physical challenges of engaging with daily 
prescribing:
“I lost my leg in 2012 from heroin injection. It is really hard to go to the chemist every day.” (female, 
35-44 years, 65 2/11)
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For one person, below, the physical challenge that he faced seemed particularly unnecessary as his 
wife had her medication delivered from the same pharmacy due to her poor health:
“I have to go to the chemist every day and I have emphysema and the mile there and back is absolutely 
killing me and I have to stop and get a breath. If I don’t go, they will stop my medication” (male, 55-
64 years, 38 2/10)
Travel time and expense of public transport to access the pharmacy was also acknowledged by a 
few participants: 
“I have to go a fair distance as my chemist more locally only takes on one at a time. It costs £3.80 on 
the bus and I don’t always have that so I have to walk miles.” (male, 35-44 years, 82 3/342)
“It wasn’t made clear that not all pharmacies dispensed buprenorphine. So, I had a bit of any issue 
trying to find my own pharmacy. I was not told that it would need to be daily dispensed. A six-mile 
round trip, £4.80 on a bus. I was only able to afford to go as I can travel as a companion on my mum’s 
bus pass. Without this, I would have to walk, which I would have, but there is no help available to pay 
for travel” (female, 45- 54 years, 86 3/354)
Reflecting on changes to dispensing arrangements over the pandemic, 55 % (N=52) would like a 
change to their current dispensing arrangements.
Two participants would like an option of splitting their dose:
“I would like to take some (medication) away with me so I can split my dose.” (female. 35-44 years, 
60 2/13)
Few participants acknowledged that addiction staff had explained conditions to reducing frequency 
of dispensing arrangements, with one individual feeling fully informed of the process:
“It was supervised daily and they saw I was going every day so I got the option to go less” (male, 
24-34 years, 6 3/199)
“Fully informed on what it would take to go twice a week and then weekly. It is mandatory daily until 




For 15% (n=14) of participants, this was their first and only experience of treatment. The vast 
majority, 85% (N=81) had previous experience of treatment, with 64 % (N=61) having experienced 
multiple episodes of three or more periods in treatment. 
Extra Support
Participants were asked, if for their current time in treatment, had they ever felt in need of extra 
support. Table 15 shows that the majority of responses 76% (n=72) felt that this was the case at 
some point.
Table 15: Extra support.
Have you had times on your 





Not sure 3 3
Total 95 100*
*Percentages have been rounded to the nearest whole number which may result in total adding to more than 100%
For this group, having someone to talk to would have helped:
“A few times I have just been fed up with it. I told the service but there was a six-week waiting list 
to get to speak to anyone. My dose has never been reviewed. I wanted more support but not an 
increase in my medication. I needed someone to talk to.” (male 35-44 years, 14 6/7)
“When I split up with my partner, I could have done with help, but my worker wasn’t in contact with 
me at all.” (female 24-34 years, 52 6/15)
“All the way through I have felt the need for extra support, and it shouldn’t be like this. I don’t feel 
able to talk to a worker, there is a lack of trust on both sides. They are not interested.” (male, 35-44 
years, 91 6/21)
When asked to give examples of,’ what type of support helped’, increased frequency of contact 
with a service alongside having a therapeutic relationship, which supported participants to self-
determine their recovery helped to keep people engaged with services:
“Now I am going twice a weekly it used to be weekly, but it has recently changed (name of 3rd sector 
service) have been pretty good with extra support.” (male, 24-34 years, 6 6/24)
“I have had low periods when I struggled. I often miss my meth and the service heard about that and 
they try to see me earlier than my scheduled appointment. It was very much my choice if I felt I had 
to increase my dose and I have a good worker, so I felt I was listened to and I was happy to discuss 
things.” (female, 45-54 years 20 6/29)
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Additionally, access to community psychiatric nurses for mental health support was cited as an 
important factor of support.  Community based third sector services were also rated as important 
points of support and as gateway to access to other services. However, access to all aspects of 
support were variable in and between different health board areas:
“Where I am at this time round, I feel I have all the help that I need. Previously, especially over 
lockdown, you were just left to get on with things yourself which is why I ended back out of treatment 
and using again.” (male, 24-34 years, 4 6/240)
Dropping out of service
Table 16 quantifies the number of participants who feel they have had times when they felt at risk 
of dropping out the service.
Table 16: Risk of dropping out.
Have you had times when you 






*Percentages have been rounded to the nearest whole number which may result in total adding to more than 100%
Majority of participants identified needing support for their mental health. Participants found it 
difficult to articulate the constituent parts of what mental health support would need to look like, 
but currently felt their mental health needs were not being adequately assessed and addressed.
“It is really hard just now but it is down to my mental health, trying to keep appointments when you 
are paranoid and anxious makes things really difficult. You don’t want to go out the house. I am 
getting extra support this time round because I am pregnant. I feel I have more support.” (female, 
35-44 years, 10 6/166)
Participants acknowledged that the pandemic has been a challenging time for services however 
recurring themes of poor communication and changing staff have been identified as areas for 
improvement.
This is exemplified for one participant who had started treatment twice in the past year:
“I couldn’t phone them as I had three workers in the past year and didn’t have that kind of relationship 
with them to phone and say, ‘I am struggling a bit today.” (male, 45-54 years 22 6/145)
           
Safety Net
For the 44% (N=42) who answered ‘no’ to having times have they may have been at risk of dropping 
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out of service, for a few participants this was around fear of withdrawals, having to start treatment 
again and needing their medication too much to drop out of service rather than with a general 
overall satisfaction with treatment services.
“I have never felt the need to drop out as I need my medication too much so that keeps me going.” 
(female, 24-34 years, 94 6/247)
“My script is my safety net. I need that too much to risk dropping out.” (male, 35-44 years, 58 6/239)
Experience of service
Safety
Table 17 shows that the majority of people feel safe when engaging with different aspect of treatment 
services.
Table 17: Feeling safe to engage with the addiction service





Not sure 4 4
Total 95 100*
*Percentages have been rounded to the nearest whole number which may result in total adding to more than 100%
Responses were focused on feeling physically safe to access service premises. It was acknowledged 
that social distancing requirements of Covid 19 had increased feelings of physical safety due to 
reducing gatherings inside and outside the services of other people in treatment.
Few participants acknowledged that although they felt physically safe to access services this did not 
equate to feeling emotional safety:
“I feel physically safe, I just don’t feel supported.” (male,45-54 years, 37 7/42)
Two of the six female participants with children, illustrated the challenge for mothers to feel 
emotionally safe in services:
“I know a lot of mothers who go in there and don’t tell the truth for fear of losing their kids.” (female, 
35-44 years, 89 7/118)
“When you have weans you can never trust them. You can never tell the truth. My worker is a nice 
person, but it is her job to feed back if I fucked up so the consequences of telling the truth are too 
great” (female, 35-44 years, 34 7/120)
A further few participants continued this theme around concerns of confidentiality across services.
“You are scared to talk to them in case they pass it on to like social worker, DWP, they would stick you 
in it.” (female, no children, 35-44 years, 23 7/116)
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One noting that that some services are not adequately private:
“I feel safe but worry that everyone can hear what you say as when you are outside you hear 
everything that is going on inside.” (prefer not to say,24-34 years, 40 7/119)
For this group physical safety was only one aspect of measuring, ‘feeling safe’ to engage with services.
Addiction staff
Table 18 participants were asked to state if they feel supported by their support worker in addiction 
services.
Table 18: Support in addiction service
Do you feel supported by your 
support worker in addiction 




Not sure 11 12
Missing 1 1
Total 95 100*
*Percentages have been rounded to the nearest whole number which may result in total adding to more than 100%
There was a wide variation in types of workers supporting participants within addiction service. 
Majority of participants responded to this question by focusing on the key member of staff who they 
have most contact with. For some individuals this was a support worker or CPN and others named 
addiction or social worker staff.
In terms of worker competencies, which were viewed to have the biggest impact, support and 
accessibility of worker was a recurring theme: 
“I have my workers mobile, and I can phone out with working hours, and they will get back to me in 
work hours. This is good as I suffer anxiety.” (male, 45-54 years, 45 7/2)
Additionally, a worker recognising difficulties with engagement and working creatively to overcome 
obstacles to accessing support increased satisfaction with services:
“My worker lets me wait outside for appointments when my anxiety is bad.” (female, 35-44 years, 
55 7/34)
Majority of participants stated the importance of having a connection with your worker, regardless 
of their professional qualification:
“I feel my worker is really caring and I feel I have a connection and that she always looks out for me. 
This hasn’t always been the case with previous workers.” (female, 35 - 44 years, 15 7/12)
For a few respondents’ workers having their own experience of treatment was valued:
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“It helps to have some of the services that I use employ people who have been there. Life experience 
is your best asset when dealing with people who use drugs”. (female, 35-44 years 8 7/7)
Majority of respondents reflected that ‘luck’ played a hand in how you are paired with a worker and 
this ‘luck’ can facilitate retention or drop out in treatment. One person suggested that having a say 
in your worker should be part of a review process to increase retention in service:
“I feel alright with services, but it took a while to get a worker that I feel I get on with……. You should 
be asked after 6-8 weeks, ‘Do you get on with your worker?’. Having a good rapport with your worker 
has a lot to do with your recovery.” (male, 35-44 years, 7 7/6)
Prescriber
Table 19 below displays participants response to the question of, do you feel supported by your 
prescriber?
Table 19: Prescriber and support





Not sure 9 10
Total 95 100*
*Percentages have been rounded to the nearest whole number which may result in total adding to more than 100%
This question proved difficult for respondents to answer without significant explanation and probing 
from peer researchers.
Further analysis of the qualitative responses to this question reveals a more complex picture, amongst 
the 47% (N=45) yes responses; it was clear that many people did not know who their prescriber was. 
Respondents described a culture of prescribing as remote, with missed opportunities to explain 
issues pertinent to their recovery such as negotiating a therapeutic dose. The narrative was around 
limited opportunities to review dose and choice of medication.  
“I have no idea who my prescriber is and currently feel I have no say in treatment.” (female, 45-45 
years, 5 7/150)
“I don’t get to see the doctor who writes my script. The script is already written, and I don’t get to 
discuss anything with them at all. I have to speak to my worker to pass on a message”. (female, 35-
44 years,15 7/127)
“I have never met my prescriber, never had a phone call, no opportunity to review things. I only know 
it (who prescriber is) from my prescription. My worker passes on information to the doctor.” (female, 
24-34 years, 37 7/136)
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For participants who felt supported by their prescriber a feeling of being in control of their recovery 
was a key measure of support:
“I have a really good relationship, he lets me control my own recovery, he never imposes his will. 
Always dead fair but won’t take any snash”. (male ,35-44 years, 76 7/206)
“If you have a problem with your dose you can talk to them. I had to talk to them about getting an 
increase after I used kit once. They understood the circumstances”. (male, 35-44 years, 82 7/205)
Pharmacy
Table 20 displays responses to the question of, do you feel supported by your pharmacist.
Table: Pharmacy and support





Not sure 13 14
Missing 3 3
Total 95 100*
*Percentages have been rounded to the nearest whole number which may result in total adding to more than 100%
Notwithstanding the previous themes discussed in dispensing section (see page 24), pharmacists 
and pharmacy staff were valued as having a key role in support. Many participants acknowledged 
being referred to by name, short waiting times and having access to a private consultation room 
as all facilitating a supportive environment. Additionally, pharmacists were seen as having a key 
mediating role with addiction services and accessing medical care:
“They don’t look down on you and you never have to wait too long. They always reassure you. If they 
were bad that would be a big turn off. My worker works with them, and they will pass on messages 
via her to me”.  (male, 35-44 years, 27 7/272)
“More so than the service (addiction), they see you every day and are able to build up a relationship. 
I had phoned my service when I had to self-isolate, and the service didn’t get back to me, so I missed 
a dose. The pharmacy sorted it out and are now dropping off my medication. The pharmacy phone 
the service for me and left a message that I was self-isolating. The pharmacy are really great at 
communicating.” (female, 24-34 years, 92 7/294)
“When my partner died of a drug overdose, they were really supportive and gave me numbers and 
tried to link in with services”. (female, 35-44 years, 11 7/264)
A few responses stated the importance of pharmacy staff demonstrating care and concern for the 
individual’s general presentation:
“They ask me how I am. I don’t feel they report back if I am under the influence. They just don’t give 
you your script that day and there is no issue the next time you go in, they just ask after you and 
check you are okay” (female, 35-44 years, 21 7/270)
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“Staff in the pharmacy are great, they are always asking after my son. They treat you like you are 
normal. It makes you happy that people actually care”.  (female, 24-34 years, 35 7/275)
“All the staff are brilliant. They care, they ask how you are and ask if there is anything they can do to 
help if I am looking rough”. (male, 35 – 44, 21 7/271)
For participants who responded, ‘no’ and ‘not sure’ to the question of feeling supported, the 
sentiment was feeling they were treated differently from other customers adding to the stigma 
of accessing services. Five responses mentioned examples of being treated as a “second class 
citizen” regarding waiting times and non-MAT customers receiving preferential treatment. This was 
compounded in pharmacies who relied more on locum pharmacists which was viewed as inhibiting 
opportunities for forming positive relationships.
 “It is a big step going to the chemist and being told to stand left, it’s just you are treated differently”. 
(male, 35-44 years, 79,7/308)
“I am sometimes in for 30 mins and people that come in after me get served first. My worker (at 
supported accommodation) was horrified at how I was treated in there. You are treated like a second-
class citizen, there is no conversation or concern that your script has been reduced they only do it 
cause they are paid too.” (female, 24- 34 years, 37 7/302)
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Discussion
Demographic Characteristics of sample cohort
For this sample of 95 people in MAT, 59%* (n=56) lived alone. When considering the 6% (n=6) of single 
parent households, the number of participants as the only adult in a household increases to 65% 
(n=62). This increases to 77% (n=43) when considering participants aged 35 and above. This reflects 
the age range of participants in, Older People with Drug Problems in Scotland Report (SDF,2017)7 
which found that 78.9% of their study sample lived alone; this is comparatively higher than the 
general population of 36% (NRS,2018)8 who live alone.  These demographics are consistent with 
the findings from Older People with Drug Problems in Scotland Report which highlighted themes of 
isolation and loneliness for this demographic. 
A considerable proportion of respondents 44%* (n=42) lived in temporary accommodation indictive 
of a transient population. This reflects other literature on the huge cross over between problem 
substance use and homelessness9. Participants post codes mirror some of the most deprived areas of 
Scotland10. This is not a moot point; drug related deaths are 18 times more likely to occur in the most 
deprived areas of Scotland2. A total of 85% (n=81) have had two or more treatment episodes. Of this 
85%, 64% (n=61) have had three or more treatment episodes. When asked the longest period that 
they had ever consistently spent in services 39%* (n=37) have experienced retention in treatment 
for more than three years, at some point and for 33% (n=31) their longest period of treatment is 
less than two years. As people are subsequently seeking to re-access treatment, often within a very 
quick timeframe of exiting service; this figure implies that people are not getting the level of support 
required for retention in treatment long enough for services to provide care for physical, emotional, 
and social needs for people to subsequently exit services and successfully move on. Additionally, 
there was evidence of punitive treatment impacting on retention with people describing changes 
to MAT for missing appointments. The evidence base on rewards and contingency management is 
clear; positive feedback, encouragement and acknowledgement of incremental progress is linked to 
stabilisation on medication (DoH,2017: p.57-58).11
Access
For the 8% (n=8) of participants who had received same day prescribing their satisfaction with the 
service was high. Amongst the remaining 92% (n=87) of participants it was broadly acknowledged 
that waiting times have improved across all 6 health board areas and increased satisfaction with 
services in this regard. For those participants who described increased risk while they waited for 
MAT to commence it is important to stress that for some people the wait and risk-taking period is 
greater as there was evidence of ambivalence before contacting a service. Participants in this group 
internalised blame for failing to meet access criteria on themselves rather than on the system of 
services designed to support them. It was acknowledged that as withdrawal from society is often a 
coping mechanism rather than non-engagement, it is key to understand ‘non- engagement’ thorough 
this lens and for services to target such groups by displaying encouragement and demonstrating 
that they care; to empower access to the right support, at the right time thus ensuring equitable 
access. Over supervised and appointment-based systems were viewed as barriers to access. The 
engagement phase within treatment is crucial for positive engagement with services, retention in 
treatment and ultimately positive outcomes for people’s recovery. It is also a crucial intervention 
point in which to reduce drug related deaths. (NHS Health Scotland, 2017)12. The Drug Misuse and 
Dependence; UK guidelines on clinical management, outline MAT as one of the “key drivers of early 
engagement” (DoH, 2017: p.65)11, this point is echoed by participants here and outlines the crucial 
role of same day prescribing.
Considerable discussion focused on access and adequate medication dose as the most important 
harm reduction intervention for this group. These findings echo good practice indicators for OST 
in Staying Alive in Scotland (SDF,2019)13. For some participants, ability to engage fully in MAT was 
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impaired by their need for a benzodiazepine prescription to stabilise their illicit use. There was 
evidence of lack of access to benzodiazepine prescription to either detox or stabilise thus increasing 
risk by causing disruption and discontinuity of care received for opioid use.
This sample displayed hesitancy when prompted around other types of harm reduction intervention 
and this is an area requiring further research. Whilst not explicitly asked about Naloxone, 43 % 
(n=41) of participants had Naloxone. This number may be higher, future work would need to ask this 
explicitly. Of the 43 % who had Naloxone further research is needed in terms of how people at risk 
plan to use it and this is particularly relevant given the high percentage of people who live alone.
Data collection took place at the height of Covid 19 restrictions in 2021 and this had a detrimental 
impact on support received during this time. Most participants acknowledged the difficult 
circumstances that services were working under and were understanding of constraints placed on 
individual workers. For some people new ways of delivering service such as telephone support and 
fewer people in clinics increased satisfaction with services as such these new ways of working may 
increase retention in services post pandemic.
Choice
For participants who stated they had adequate support and information to make an informed choice 
in relation to medication and dose received they expressed an overall positive experience of MAT. 
The degree of involvement with decision making, feeling listened to and having opportunity for 
meaningful input into clinical decisions improved individual experience of services. This must be 
balanced against participants who felt that although information was provided, they did not feel 
included in decisions made in relation to medication choice or dose and acknowledged feeling less 
satisfied with services as a result, in particular increased dose without informed consent heightened 
dissatisfaction with services. 
Participants described a range of needs which required to be addressed on presentation to services. 
Receiving the right medication was seen as imperative to moving beyond drug use and achieving 
wider social connections to addressing these other presenting issues. As illustrated by participants, 
when they were asked to describe, ‘what things were like for you when you waited to start treatment’, 
consideration needs to be given to the physical and mental health status of people presenting to 
services.
Opportunities for choice often take place in the context of people seeking treatment experiencing 
physical withdrawal. Textual analysis highlighted the importance of reducing the titration period for 
people to hasten stabilisation, reduce harm and to improve retention in service. Evidence connects 
the first four weeks of starting treatment and the first four weeks after leaving treatment with an 
increased mortality risk (SG, 2021: p.6). Trujols et al. (2019) cited in MAT standards p.484, identified 
that a person’s dose adequacy is influenced by care they receive and not just pharmacological effects 
of MAT. This sample supports this finding, ultimately that meaningful inclusion over treatment 
decisions will result with increased satisfaction with services. It is crucial in order to improve retention 
in treatment, that all decisions feel informed and consented to. Seen in this context, choice is more 
than simply empowering people seeking treatment; it is ensuring staff have the resource, time 
and adequate training to facilitate conversations about treatment choices. Offering such choice, 
fundamentally increases retention in services and ultimately saves lives which is at the very core of 
the MAT standards.
These interviews revealed a group of people desiring to be more involved in their treatment and a 
group who wish to be more involved in all aspects of their care.  Arguably a more engaged group, 
is to be expected from any self-selecting sample however it does challenge some of the negative 
stereotypes of drug users both in services and depicted by wider society, as highlighted by UK Drug 
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Policy Commission (2011)15, around assumptions concerning people’s ability to change. 
Throughout discussions on choice, it was evident that there is infrequent opportunity to review 
medication and dose. This lack of opportunity to review treatment was also evident in discussions 
around frequency of attendance at pharmacies.  Over half the sample 55% (n=52) would like a 
change to their current dispensing arrangements. Experience of attending pharmacies less over the 
course of the pandemic has perhaps fuelled this as more people have experienced managing their 
medication in a different way; the pandemic, initially, reduced daily dispensing. Daily attendance at 
the pharmacy had a protective factor for some, for others daily attendance was viewed as punitive 
treatment and reinforcing stigma of drug users by the wider population. Options for alterations 
to prescribing regimes including take home prescriptions are outlined as important incentives for 
recovery in the Drug Misuse and Dependence; UK guidelines on clinical management (DoH, 2017)11. 
The important role of pharmacy-based prescribers in people’s treatment was evident in this sample, 
where opportunistic care by pharmacy staff was broadly welcomed by participants but having the 
choice to engage less was more highly valued.
Support
As discussed above, participants in this study have experienced multiple episodes of MAT. For this 
sample 76% were able to identify specific times when they required extra support. Qualitative 
findings outlined that the majority of people required additional support around mental health in 
particular. There are significant challenges in accessing mental health support especially in regard 
to psychological services, where stability within substance use prior to commencing psychological 
treatment is recommended (SG, 2018)15. This further highlights the crucial role of MAT within 
addressing people’s mental health issues; it is also important to note that psychological therapy 
enhances the outcomes of OST (SG, 2018). The balance of optimal dosing recommendations (DoH, 
2017)11 and issues pertaining to possibilities of impaired cognition for psychological therapies for 
those in receipt of common optimal dose ranges of MAT (SG, 2018) can serve as a barrier to accessing 
mental health supports and needs further consideration within treatment to avoid people falling 
through the gaps.
The experience of participants is suggestive of variable support availability, in and across, different 
health board areas of what to expect and of support received. It was acknowledged that changes of 
named worker and ability to communicate easily with services had been made more difficult during 
the pandemic.  People know when they required support; the challenge to practice, is in how to 
succeed in giving care and support in a timely fashion, to ensure retention when people may not feel 
secure enough to disclose these feelings to service. This is especially pertinent as 56% of participants 
have considered themselves at risk of dropping out of service at some point. Participants spoke 
about the difficulty of contacting a worker when there had been little time to build up a therapeutic 
relationship due to repeated staff changes.
A total of 76% felt physically safe to engage with services however the barrier was in feeling 
sufficiently emotionally safe to ask for help and concerns that asking for support could result in 
punitive treatment; this was a particularly strong theme for female participants with children. This 
finding regarding females and treatment and care was also highlighted in SDF and Dumfries and 
Galloway, Alcohol and Drug Partnership report into treatment and care needs of pregnant women 
who use substances15. Given the high rates of trauma within this population (SG, 2018), it is key to 
address issues around emotional safety which is outlined as a key principle in providing trauma 
informed care (SG, 2021)17. The findings suggest, there is work in service to be done to enhance 
feelings of emotional safety by reducing instances of or concerns about punitive practice which act 
as a barrier to engagement.
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For the 44% who felt that they were not at risk of dropping out of service this was around their 
need for medication rather than overall feeling satisfied with the service. Worker attributes that 
increased engagement with service focused on: accessibility; easily contactable; recognising 
obstacles and removing barriers to access. Overall, having a connection was more highly valued than 
professional background of worker. Frustration for some participants was on the element of luck 
with regards to allocation of worker. As connection is so important to promoting emotional safety 
within services then this should be an area where more consideration is given to improve care and 
support received. This finding is supported in the Drug misuse and dependence; UK guidelines on 
clinical management, (DoH, 2017: p.53)11 which provide the evidence base for the importance of a 
good therapeutic alliance in delivering any treatment intervention.
Pharmacy staff were viewed as having a key role in providing care, support and in mediating with 
addiction services and medical care. The support area that participants expressed most dissatisfaction 
was around their relationship with their prescriber. Of the 95 participants, 47% felt supported by their 
prescriber however on further probing around, ‘which aspects of their support people valued’, it was 
clear that people were confused as to who their prescriber was. This impacted on ability to access 
and review appropriate treatment. This contrasted with individuals who had a good relationships 
with their prescriber who felt in control of their recovery and decisions made in relation to MAT. 
Conclusion
This baseline evaluation of people’s experiences of accessing MAT in Scotland indicates why the 
implementation of the MAT standards are crucial to how people access and experience MAT across 
Scotland. The experiential narrative gives insight into ways in which action can reduce both drug related 
harms and drug related deaths by increasing satisfaction with services with same day prescribing, 
choice of treatment and subsequent retention. This snapshot illustrates the issues faced by people 
who are not retained in services long enough to access support needed to address presenting issues. 
It highlights that retention is a major issue and reinforces other studies SDF have undertaken. This 
work was intended to shed light on the current living experience of people using services and in 
doing so provide an overall picture to inform quality improvement at local and national levels. The 
findings outline the challenge is in the how to move from where we are, to where the MAT standards 
require services to be. This report suggests further work on implementation should consider actions 
in the following areas as both specific challenges and opportunities for improvement.
Access
Service models need to reflect the reality of the living situation of the people they are trying to 
reach. Isolation, social deprivation, and transient populations require services to meet them where 
they are at. Low threshold services which acknowledge and respond directly to these barriers need 
to be a first step.
Same day prescribing is essential, delivery models which facilitate this should be replicated and 
adapted to suit local circumstances. Faster processes for restarting MAT need to be developed to 
reduce disruption to MAT and deliver same day restarts.
Given the role of illicit benzodiazepine use in participants ability to engage with OST, increasing 
access to benzodiazepine detox and provision of maintenance prescriptions as a component of MAT 
should be available where required and clinically appropriate.
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Choice
For people using services, seeing change is crucial. Autonomy and choice in making treatment 
decisions need to be at the heart of service improvement. Providing adequate information on 
options of medication and dose is necessary to empower people to have meaningful input in their 
care. Equitable access to a range of treatment options, in and across health boards, in order that 
choice of intervention is supported regardless of location. To address treatment holistically and 
taking account of barriers such as poor mental health, treatment support should include access to a 
range of psychosocial supports.
Support
Covid 19 has shown, in some areas, that service can be improved by creatively engaging people. 
Providing support which recognise the importance of connection within all aspects of care is key to 
providing emotionally safe environments for people to engage without fear of punitive responses. 
People need to feel listened to and able to discuss their life without fear; some aspects of current 
service design precludes engagement for some people. Responding in ways to develop trust is critical 
for all groups but especially important for females with children. Ways to establish and maintain 
meaningful therapeutic relationships should underpin all that services do. There is an opportunity 
for therapeutic relationships to develop across the wider system of care and it is key that staff in roles 
with less focus on the therapeutic alliance such as pharmacy recognise the importance of their care 
and support in treatment retention. The gaps in access to additional support, in particular to mental 
health supports are evident. Services should proactively offer additional support at regular intervals 
to prevent missed opportunity for engagement and to review treatment goals. Treatment pathways 
between substance use and mental health services should be further developed to reflect the reality 
of people who have comorbid substance use and mental health problems and are accessing MAT.
Across the themes of access, choice and support, practice which is identified as disrupting delivery 
of MAT need to be eliminated if the MAT standards are to mark a watershed moment in reducing 
drug related harms and drug related deaths in Scotland.
Considerations for practice
The findings from this evaluation of people’s experiences of accessing MAT, suggest a number of 
considerations for practice as services progress with implementation of the MAT standards. These 
are outlined below.
Access
	Addressing barriers to access: Physically taking services, by increasing assertive outreach 
models to the most deprived areas will allow people the chance to talk and be listened 
to. This is a crucial first step to getting people into treatment by allowing opportunities to 
counteract their experience of endemic isolation.
	Same day prescribing: It is key that staff across all sectors take responsibility for raising 
expectations of faster access to treatment crucially, access to same day prescribing needs to 
mean same day. By informing people of the process of starting MAT expectations of receiving 
treatment upon your first contact with the service will create a cultural shift away from low 
expectations within this population.
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	Harm reduction: Services should explore meaningful initiatives and new strategies to engage 
people receiving MAT in wider harm reduction advice and support in order to increase uptake 
and provide support to people most likely to benefit from this. The Glasgow City Council 
WAND initiative (Wound Care, Assessment of Injecting Risk, Naloxone and Dry Bloodspot 
testing) is one such example of an approach using a contingency management model to 
reduce harm amongst people who inject drugs18
Choice
	Offering choice and involvement in care planning: Care planning needs to be a collaborative 
process, with timely, regular reviews. The role of the prescriber must be clarified to ensure 
adequate opportunities to discuss medication choice and dose and allow immediate changes 
to medication if required. In particular this means that all people using MAT should know 
who their prescriber is. Conversations should also include exploring and reviewing dispensing 
arrangements such as opportunities for take home prescriptions.
	Training, information and communication: Staff across sectors should have access to up-to-
date information and training on MAT treatment options in order to be able to effectively 
inform their service users. Services should consider different mediums of sharing information 
with service users which support in person communication, this could include leaflets or 
digital resources.
Support
	Developing support pathways: Service delivery should ensure that the experience of people 
using services is taken into consideration to develop support pathways that currently do not 
exist for them to access the right level of support, at the right time, and by the right people. 
Particular attention to addressing the pathway into mental health support should be given 
to avoid people falling through the gaps of being unable to fully engage in MAT due to their 
mental health, yet unable to access adequate mental health support when in receipt of MAT.
	Developing therapeutic relationships: It is crucial to recognise the importance of connection 
in developing therapeutic relationships between staff and people accessing treatment and 
equally important staff need to be willing to review this when people in treatment feel, for 
whatever reason, that a connection is not there. Continuity of support, including changes to 
named workers should be minimised to allow development of therapeutic alliances with key 
staff. Staff within the wider system of care such as pharmacy staff, have a key role to play in 
developing therapeutic relationships and should aim to strengthen these engagements, no 
matter how brief, ultimately helping to retain people in treatment.
	Challenging stigma: To change the experience of stigma for people using services, the 
workforce training and development needs to lead to a culture change which is more trauma 
informed in order for people to feel emotionally safe to disclose their needs and barriers 
which may affect their engagement without fear of sanctions or removal of services. This 
is particularly an issue for woman with children who wish to access services and have a 
strong fear of losing custody of their children. Targeted supports which take account of the 
particular needs of women would be beneficial.
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Appendice 1: MAT Participants flyer
VOICES OF PEOPLE WHO RECEIVE
MEDICATION FOR THEIR DRUG
PROBLEM NEEDED
We're looking for people to share their recent experiences of
accessing and receiving Medication Assisted Treatment (MAT). 
MAT is otherwise known as Opiate Substitution/ Replacement
Treatment, and includes medicines like methadone and
buprenorphine.
Interviews will be carried out over the phone with a
trained peer researcher and information shared will
be kept confidential.
£10 
Part of the MAT Study of
Current Practice in Six Health
Board Areas Across Scotland 
December 2020 - April 2021
Have started or re-engaged with a service in the last 18
months and are receiving medication for a drug problem
Are 18 years or older
Live in Ayrshire and Arran, Grampian, Greater Glasgow
and Clyde, Lanarkshire, Lothian or Tayside
We want to talk to people who:
People who take part will receive a £10 shopping
voucher to thank them for their time.
To take part or for more infomation, please contact 
Joan Walsh at joanw@sdf.org.uk or call/text 07570683063
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Appendice 2: HMP Perth Cohort
Executive Summary
Background
In July 2021 1339 drug related deaths (DRDs) were recorded in Scotland, the highest number on 
record.  To put this in context, National Records of Scotland estimate this figure to be three times 
that of the UK1. To reduce DRDs and other harms associated with drug use, Medication Assisted 
Treatment (MAT) Standards for Scotland were published in May 2021, with the aim to deliver and 
measure a no barrier, consistent access to treatment regardless of individual circumstances. This 
project sought to provide a baseline of current MAT provision, prior to implementation, from the 
perspective of people currently in treatment in six health board areas. It is intended to be a reference 
point to inform and improve practice in relation to implementation of MAT.
After seeing a recruitment flyer for the Medication Assisted Treatment (MAT) project, HMP Perth 
Offender Outcomes Unit Manager (acting) approached SDF with an offer of support to include a 
prison cohort in the work. Discussions took place between SDF, prison and NHS healthcare staff to 
plan and manage the work. To ensure consistency with work already under way, the questionnaire 
already in use, was refined for a prison setting (see appendix,6).
Methods
Prison and NHS staff promoted the work to people who met the criteria of starting treatment within 
the last 18 months either in prison or in a community setting. SDF researchers received further 
training for this phase of the project.  All peer researchers involved in the prison fieldwork were 
currently in treatment and two peer researchers had previous experience of serving a custodial 
sentence.  Telephone interviews were arranged by prison staff in 30-minute time slots. Participants 
received a £10 payment into their prison account as an honorarium for taking part. A three-
way telephone interview took place between the participant, peer researcher with an SDF User 
Involvement Development Officer (UIDO) on the line to scribe a verbatim note.
 A total of 16 participants completed an interview. 
Demographic Data
Telephone interviews were conducted over a two-week period, 16 people participated. All 
respondents identified as male. The most common (mode) age range of participants was in the 35 
– 44 years old age bracket. Participants were resident in Tayside and Fife health board areas before 
entering prison. Currently prescribed medication for MAT: 44% buprenorphine;44% methadone; 6% 
detox to start methadone;6% reduction to start long-acting buprenorphine. All participants currently 
in receipt of medication assisted treatment; 12 in treatment immediately before entering prison and 
4 participants not in treatment prior to sentencing. Fourteen participants were currently on remand 
awaiting a court hearing, 2 participants nearing the end of a custodial sentence.
Findings
Thematic analysis was undertaken on all 16 participant interviews. Key findings were:
	There was a limited understanding of the process of accessing MAT in prison.
	Missed chemist doses and time in police custody prior to being remanded in prison 
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severely disrupted MAT.
	Frustration with time delay in recommencing MAT to appropriate level for those who were 
in receipt of MAT in the community prior to entering prison.
	For participants not in MAT when remanded, at least two week wait from referral to 
starting MAT.
	Main area suggested for improvement was faster access to MAT, although 
acknowledgement that waiting times have reduced from previous prison experience.
	Having options and process of MAT explained increased satisfaction with treatment.
	Discussion around dose did not always translate into a shared decision.
	Low literacy levels made understanding options difficult for some participants.
	Stability and safety net of MAT given as reasons for continuing treatment in prison.
	More access to staff support especially during titration and when starting treatment would 
increase satisfaction with service.
	75% of participants have felt the need for extra support at some point.
	More support for mental health required. 
	Staff time and encouragement to engage with services viewed as key attributes of worker.
	Some participants stated they were less likely to drop out of MAT in prison compared with 
community setting.
	Acknowledgment that the pandemic has limited support options available with increase 
isolation in cells.
	Most participants felt safe to engage with services although the process of referral and 
delay in response were areas identified for improvement.
	Prison officers and other prisoners valued as having a key intermediary role in signposting 
to services.
	Largely, based on previous experience, participants were confident that their MAT would 
continue in the community however there was some concern about what would happen to 
treatment on being released straight from court.
	Overdose training and information highly rated although some participants expressed 
concern about the time it could take to get Naloxone if they witnessed an overdose.
Conclusion
This baseline study indicates why the implementation of the MAT standards are crucial to how 
people access and experience MAT within a prison setting. The experiential narrative gives insight 
into ways in which action can reduce both drug related harms and drug related deaths by increasing 
satisfaction with services with same day prescribing, choice of treatment and subsequent support. 
This snapshot illustrates some of the challenges of implementation within a prison environment. This 
57
prison baseline study aimed to be consistent with interviews already under way in the community. 
It demonstrated that the peer research model is transferable to a prison setting and should be an 
approach built into the planning stages of any future work into service user experience of the MAT 
standards. It highlights that fast access to treatment and ongoing support are issues for this cohort. In 
line with the community survey, this work was intended to shed light on the current living experience 
of people using services and in doing so provide a starting point to quality improvement in Perth 
prison. The challenge is in the how to move from where we are, to where the MAT standards require 
all services to be. This report suggests further work on implementation in prison should consider 
actions in the following areas as both specific challenges and opportunities for improvement. A 
caveat in the following is that 14 participants were on remand and more investigation is needed with 
individuals not currently on MAT as well as people serving a sentence.
Access
The process of accessing MAT for the first time in prison and continuation of MAT from community 
addiction services need to be made clearer to those requiring treatment. 
For people who are already in withdrawals in police custody, there needs to be an urgency to get 
people stabilised on treatment as quickly as possible. Participants acknowledged a frustration 
with time delay in recommencing treatment in prison at the appropriate level. There was a strong 
motivation to remain in treatment for this cohort.
For those not in treatment in the community when remanded there requires to be faster access to 
MAT. Of the four people not in treatment in community addiction services, they all waited more than 
two weeks from referral to starting treatment. In this time potential for drug harms increased as 
reported drug use increased. The wait to start MAT also impacted on motivation to change and was 
viewed by some participants to be a missed window of opportunity. The prison and NHS healthcare 
service need to consider how they proactively identify and engage with people who use substances 
to start treatment.
Prison officers and other prisoners were identified as a good source of information on services 
available in prison and consideration should be given to approaches that capitalise on this.
For people who had previous prison experience, it was acknowledged that waiting times to access 
appropriate MAT has improved but there was still improvements to be made.
Choice
Participants felt informed about prescribing options in terms of medication available.  There was less 
agreement with this sample around involvement in decision making around dosing. The importance 
of being able to access information in an accessible format was highlighted. For participants who 
continued their treatment from the community there was missed opportunities to review dose and 
engage in the process of MAT in a prison setting.
For individuals not on treatment in the community better access and information on what is available 
to them is required.
Having adequate support is imperative to make informed choices and increase satisfaction with 
treatment services in prison. This sample suggests a varying degree of knowledge on what is available 
to make an informed choice.
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Support
Extra support is required for people when waiting to start treatment and during the titration phase.
Access to support for mental health concerns need addressed as participants expressed limited 
opportunities to speak to someone.  Service development should also be clear on proactive 
engagement of individuals who may be reluctant to ask for help. Time and encouragement from 
staff to engage with treatment services were valued attributes. 
This study provides evidence that drop out from treatment in a prison environment is less likely than 
a community setting. There is a unique opportunity in prison to engage people and provide a quality 
of care which provides stability beyond prison.
The global pandemic has limited options of interventions available and increased time spent confined 
to cells.
The intermediary role of prison officers was viewed as key to linking with other services, this should 
be acknowledged and developed. People felt safe to engage with services on offer although the 
process of referral and delay in response results in appropriate help by the right people at the right 
time being missed. There was limited understanding of the roles of addiction worker and prescriber. 
Continuation of support on release from prison requires to be strengthened.
Potential time delay in administrating Naloxone was also highlighted as an area for improvement.
In line with the community survey, across the themes of access, choice and support, practice which 
is identified as disrupting delivery of MAT need to be eliminated if the MAT standards are to mark a 
watershed moment in reducing drug related harms and drug related deaths in Scotland.
Background
In July 2021 1339 drug related deaths (DRDs) were recorded in Scotland, the highest number on 
record.  To put this in context, National Records of Scotland estimate this figure to be three times 
that of the UK1. To reduce DRDs and other harms associated with drug use, Medication Assisted 
Treatment (MAT) Standards for Scotland were published in May 2021, with the aim to deliver and 
measure a no barrier, consistent access to treatment regardless of individual circumstances. This 
project sought to provide a baseline of current MAT provision, prior to implementation, from the 
perspective of people currently in treatment in six health board areas. It is intended to be a reference 
point to inform and improve practice in relation to implementation of MAT.
After seeing a recruitment flyer for the Medication Assisted Treatment (MAT) project, HMP Perth 
Offender Outcomes Unit Manager (acting) approached SDF with an offer of support to include a 
prison cohort in the work. Discussions took place between SDF, prison and NHS healthcare staff to 
plan and manage the work. To ensure consistency with work already under way, the questionnaire 
already in use, was refined for a prison setting (see appendix,6).
Methodology
Prison and NHS staff promoted the work to people who met the criteria of starting treatment within 
the last 18 months either in prison or in a community setting. SDF researchers received further 
59
training for this phase of the project.  All peer researchers involved in the prison fieldwork were 
currently in treatment and two peer researchers had previous experience of serving a custodial 
sentence.  Telephone interviews were arranged by prison staff in 30-minute time slots. Participants 
received a £10 payment into their prison account as an honorarium for taking part. A three-
way telephone interview took place between the participant, peer researcher with an SDF User 
Involvement Development Officer (UIDO) on the line to scribe a verbatim note.
 A total of 16 participants completed an interview. 
Strengths and Limitations
A possible limitation of this work was the cohort was not part of the original project planning and 
as such a limited period was available to plan this phase with no scope for pilot interviews prior to 
fieldwork period.
The strength of this work was demonstrating the adaptability of the peer research model to a prison 
cohort. Considering the additional risk of the prison population to drug harms and drug related 
death, this work demonstrated that this group can be successfully engaged with to have their voices 
heard in how they experience services and should be part of planning for any future consultation of 
MAT.
Demographic Data
Telephone interviews were conducted over a two-week period, 16 people participated. All 
respondents identified as male. The most common (mode) age range of participants was in the 35 – 
44 years old age bracket. Table 1 displays the age categories of participants.
Table 1: Age categories of participants







*Percentages have been rounded to the nearest whole number which may result in total adding to more than 100%
Within this sample, participants came from two health board areas before entering prison, displayed 
in table 2: below.
Table 2: Heath board area of participants




*Percentages have been rounded to the nearest whole number which may result in total adding to more than 100%
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Fourteen participants are planning to return to the area they came from with one participant unsure 
whether to return to Fife or Tayside. One participant stated they will return to Tayside reluctantly as 
it is, “not where I would like to be” (N/P).
Participants were asked which medication they are currently prescribed for MAT. Table 3 displays 
participants current treatment that they are receiving.
Table 3: Current treatment for MAT
Current treatment N %
Buprenorphine 7 44
Methadone 7 44
Detox about to start methadone 1 6




   *Percentages have been rounded to the nearest whole number which may result in total adding to more than 100%
For this sample, table 4 displays the current length of time in treatment.
Table 4: Current length of time in treatment
Current length of time in 
treatment
N %
Waiting to start 1 6
Up to 6 months 2 13
1 year 1 6
1 year – 2 years 6 38
2- 3 years 1 6
5 years – 10 years 5 31
Total 16 100
*Percentages have been rounded to the nearest whole number which may result in total adding to more than 100%
Table 5 shows the longest consecutive time that participants have ever spent in treatment.
Table 5: Longest time consistently spent on methadone
Longest time consistently 
spent on methadone
N %
Up to 2 years 6 38
2 years to 5 years 3 19
More than 5 years 7 44
Total 16 101*
*Percentages have been rounded to the nearest whole number which may result in total adding to more than 100%
Table 6 presents how many times participants have started treatment.
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Table 6: Number of times starting treatment








Greater than 10 2 13
Total 16 101*
*Percentages have been rounded to the nearest whole number which may result in total adding to more than 100%
For this sample 12 participants were in receipt of MAT immediately before entering prison. Of the 
4 who were not in treatment, one had tried to unsuccessfully access a Drug Treatment and Testing 
Order (DTTO).
Fourteen of the participants were currently on remand awaiting a court hearing. Two participants 




From the participant responses, there was limited understanding of the process of accessing 
treatment in prison. Some individuals described a medical on admittance in which they were 
screened for drug use:  
“When I came in, I was seen by a nurse and they ask you about your drug use, and I was drug tested”. 
(C/AK)
“If you are on a script, you give a urine sample and then you have to wait for confirmation from the 
addiction service outside”. (E/AK)
Other individuals struggled to convey the process of accessing MAT. This was particularly the case for 
people who experienced an extended period in police custody before incarceration. Access to either 
continue a community prescription or access treatment for the first time was severely disrupted the 
longer someone was in police custody. The impact was further exasperated if there was a missed 
dose prior to entering police custody:
“About a week (to access treatment) in total as I had missed the chemist and was also in police 
custody”. (D/AN)
“I waited for about 36 hours to get my script, but it was quite good given all the things they have to 
check. I was in police custody prior to coming in so I had missed a good couple of days of my meds”. 
(H/AO)
“I was in a bad way and had been in police custody and had missed meds then. I was remanded on 
the Monday and think it was Tuesday evening, Wednesday morning, I think before I got anything. 
I was given 50mls and they built it up slowly. It took a few weeks to build it up. I was 110ml in the 
community. I was just left to rattle in a cell with someone else who was rattling as well. There was no 
support, the nurses didn’t come to see me, I was just left”.  (C/AO)
“Prior to being in prison I had been in a cell (police) rattling for days”. (Q/AO)
Frustration with the time delay in recommencing their community MAT on entering prison was a 
recurring theme of participants:
“I don’t see why you can’t start there and then as it would save a lot of hassle if you could just start.” 
(J/AO)
“It was pretty rough, but it takes time to check these things out, so I suppose it wasn’t too bad. I 
couldn’t sleep and was constantly checking the time, I felt sick. I have done this in jail before, so I 
knew what to expect.” (H/AP)
Additionally, one participant described the anxiety caused by not knowing the outcome of the 
assessment:
“There is a heavy fear of the unknown. You don’t know if you are going to get the script.” (6/AO)
For participants in treatment, prior to entering prison, motivation to continue MAT in prison was 
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around not wanting to have to start treatment again:
“Because I was on it outside and I didn’t want to come in here and start gubbing drugs.” (D/AQ)
“When I came into jail I was already on a script, and I don’t want to start again.” (H/AQ)
One participant, who had accessed MAT thirteen months ago, compared the experience of accessing 
MAT in prison favourably to his experience to accessing treatment in the community:
“It took 6 weeks to get started in the community, but I was able to get my script started the next day 
(in prison)”. (I/AO)
For the four participants who were not on MAT when remanded table 7 below details the length of 
time from self-referring to NHS healthcare to starting treatment.
Table 7: Length of time to start treatment in prison 




3- 4 weeks 1
1 month 2
Total 4
For all four participants who were not in receipt of MAT in the community when remanded, drug use 
increased as participants described withdrawals while waiting to access help in prison:
“Drug use really bad, I was using all the time and not caring what it was doing to me. I am trained to 
use Naloxone. The wait played on my mind, just waiting to get put on it. Now I am on it, my mental 
health is feeling a lot better”. (R/AO)
“Really hard, chasing the drugs”. (K/A0)
“Up and down.  Still taking drugs that I could buy, that were available.  My mood was low, I had got 
to the point that I needed help”. (M/AO)
“Terrible, using everything.” (Q/A0)
All four self-referred to services. One participant self-referred after being encouraged to during 
admission medical.  Three participants received no support or encouragement to self-refer. As well 
as continued risk behaviours while waiting one participant expressed concern of the wait impacting 
on motivation to change:
“You should get treatment immediately as you can change your mind while you wait.” (N/AS)
“The wait is too long; I was rattling for weeks.” (Q/AS)
“From what I heard from other prisoners it is good (once you get into treatment).   The wait is a bit 
long, doctor said it will be about 4 weeks”. (K/AS)
“If you are on remand, it is really difficult to get help especially if you are not on a script when you 
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come in.” (E/AS)
“You need to know who to ask and if you aren’t on a script, it can be hard to find out how to get help. 
You can ask a prison officer or other boys as they let you know how to get things sorted.” (H/AT)
When asked, “do you think the process of accessing treatment could be improved in any way” 14 
participants stated ‘yes’ and two participants felt satisfied with the access to treatment that they 
had received.
The main area suggested for improvement was faster access to MAT:
“It needs to be quicker. They should contact addiction service in the community quicker.” (L/AS)
“The wait is too long; I was rattling for weeks.” (Q/AS)
“They need to get the waiting time down.” (R/AS)
“What would help would be when you come in especially on remand you should get access to 
treatment quicker to stop using in the prison and to get people to be stable before they come out. It 
is a missed opportunity to keep people alive.” (E/BQ)
One participant acknowledged that access to MAT has improved:
“I think things have got better. I only had to wait three weeks to get into service here.” (O/AS)
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Choice
Table 8 and 9 below detail the responses to the question, ‘were prescribing options discussed with 
you’ and if so, was there, ‘enough information to make an informed choice?’ 
Table 8: Were prescribing options discussed with you?






*Percentages have been rounded to the nearest whole number which may result in total adding to more than 100%
Table 9: If yes, do you feel you had enough information to make an informed decision?
IF yes, do you feel you had 






*Percentages have been rounded to the nearest whole number which may result in total adding to more than 100%
For participants who felt the decisions around MAT were informed, having options and the process 
explained increased satisfaction with treatment:
“Yes, they have explained all about the (medication) and what will happen with dispensing my meth.” 
(H/BA)
“I was given the choice of meth or buprenorphine. They tell you your name is on the list, and they told 
me the amount and if I want to up my dose, I can speak to my worker.” (R/BA)
When prompted more specifically about decision making in relation to dose with the 8 participants 
who stated that dose was discussed; 6 responses stated that this discussion did not translate into a 
shared decision:
“I didn’t get an option I was told it was buprenorphine and I was told that this would be the strongest 
thing for me they never said about how rough I would feel.” (G/BA)
“Obviously meth and buprenorphine aren’t for everyone, but we need more options discussed with 
us. I only found out about Buvidal from another Con but as soon as I asked my addiction worker, I was 
given a leaflet and waiting to start.” (I/AS)
Two participants stated that no discussion took place.  For one participant his difficulty with 
understanding written information was impeded by his low level of literacy. Another participant 
stated to having no information which led him to taking his medication incorrectly:
“Nothing at all was discussed with me, on dose, dispensing or choice. The only thing you get is a letter 
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to sign that you won’t hold the medication back. You have to sign that even if you can’t read.” (E/BA)
“The first time I swallowed it, it wasn’t explained to me that I had to let it dissolve.” (Q/BA)
Participants identified missed opportunities for agency over the dose received:
“They just handed me the cup and there was only 50ml in it as they wanted to build it up slowly, but 
there is slow and then there is slow. I was put up 10 ml ever 4/5 days it wasn’t enough.” (C/DB)
“I didn’t know what I was starting on or what the plan was. My starting dose didn’t hold me. I was 
started on 20ml in prison but in Dundee they start you on 40ml. Why the difference in prison?” (E/BD)
“There was no discussion, I was told I would go on the same as I was outside. I didn’t want to go up 
or down.” (H/BD)
“I was just told that was the dose I will start on.” (I/BD)
“Everyone gets the same amount.” (O/BD)
“I wanted a lower dose, but medical staff wanted me to be higher. I didn’t want a higher dose. It 
wouldn’t have mattered what staff said or what I was offered, I knew I wanted meth as I know this 
helps me manage the pain of other strong health conditions.” (F/BD)
Eight participants commented that the timings of dispensing arrangements changed regularly. 
There was a narrative from participants around more consistency with timings although there was 
a general understanding around the difficulty for the prison to provide an alternative arrangement:
“The current way is the only way they can do it, but I would prefer my meds in the afternoon if I had 
the choice”. (P/AJ)
“I think it should be the same time every day. One day it could be 8am another day it could be at 
10am. It should be the same time every day”. (L/AJ)
Table 10 below details the responses to, “Did you have an idea of what you wanted when you first 
accessed services in prison?”
Table 10: Did you have an idea of what you wanted when you first accessed services in prison?
Did you have an idea if what 
you wanted when you first 





*Percentages have been rounded to the nearest whole number which may result in total adding to more than 100%
The yes responses all stated seeking stability as the motivation to access services in prison:
“I knew I wanted to be stable, and I knew meth could do this for me because of my experience with 
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it. I wasn’t thinking about the future or anything, I just wanted to be stable.” (F/AW)
“I wanted to feel better, I wanted back onto my meth.” (L/AW)
For participants who stated not knowing what they wanted when they first accessed services in 
prison reasons for this was around lack of information on what options were available as well as 
feeling that there could be more direct engagement from staff on admittance to prison:
“Yeah, I do now as I work well with my worker but not at the start. My worker really wants me to help 
me turn my life around. Some nursing staff are just in it for the job. You need the right person.” (C/AT)
“If you are on remand, it is really difficult to get help especially if you are not on a script when you 
come in.” (E/AS)
“More advertised regarding help in prison, not everyone knows what is on offer in prison or in the 
community………. there is leaflets everywhere but I think they should talk about it more.”
 (P/AS/AU)
Two participants commented that having more information and more access to staff would help 
them to make better choices and increase their satisfaction with treatment service in prison:
“I don’t want this yo-yo of being in and out of treatment to continue.    I understand they are doing 
other stuff because of Covid.  It would be good to get a wee chat and for people to check more how 
you are getting on and give you some positive feedback”. (D/AS)
“A lot of people are harming themself there is not enough information available or visible. Staff need 
to be getting in touch with us more and getting officers to talk to us about our mental health as that 
impacts on your drug use.   The priest welcoming you into the jail feels like a reality check and is the 




Participants were asked, if for their current time in treatment, had they, ‘ever felt in need of extra 
support?’ Table 11 shows that 75% (n=12) of participants felt that this was the case at some point.
Table 11: Have you had times on your medication that you felt in need of extra support?
Have you had times on your 
medication that you felt in 




Not sure 1 6
Total 16 100
*Percentages have been rounded to the nearest whole number which may result in total adding to more than 100%
For participants who felt they had times when they needed extra support, waiting to commence 
treatment and during the titration period were identified as key points when having contact with 
someone to speak to would have helped:
“I really struggled when I first came in and just felt like no one was listening to me.” (C/BH)
“At the beginning when I was on 16mg (felt in need of extra support), but it was okay once I levelled 
out. I would have liked more access to my addiction worker”. (G/BH)
There was a recurring theme from participants stating the importance of having someone to speak 
to specifically around mental health concerns that participants had:
“You just want to speak to someone (about mental health).” (N/BH)
“My mental health, I need extra support with this.” (E/BH)
“I have mental health issues and I don’t really feel I am getting the chance to speak to anyone about 
it.” (Q/BH)
“Mental health and things like that. In the jail it is hard, if you need to increase, they will but you 
don’t get the impression that they like doing it. They should be more understanding; they make you 
feel like you are drug seeking.” (L/BH)
Two participants reflected that they would like to have someone to speak to, but they did not feel 
able to ask for additional support:
“If I feel the dose isn’t working or feel the need for extra drugs it would be handy to have someone 
there, but I don’t speak to anyone about it.” (M/BH)
“I get a lot of depression, but I haven’t asked for any help with this.” (O/BH)
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Retention in service
Table 12 details the number of participants who acknowledged they have had times when they felt 
at risk of dropping out the service.
Table 12: Have you had times when you have been at risk of dropping out of the service?
Have you had times when you 
have been at risk of dropping 





*Percentages have been rounded to the nearest whole number which may result in total adding to more than 100%
For participants who stated there have been times when they were at risk of dropping out of service, 
one said that his mental health prevented him from speaking to staff:
“I have felt that I wanted to but then I give myself a kick in the arse and that. It is when I am depressed 
and feeling low, but I never talk to anyone in prison about this.” (P/BJ)
Another respondent felt frustrated at not being supported to make decisions in relation to his 
recovery:
“Loads of times especially when I wasn’t getting help to detox. I tell them every time I go to the hatch. 
All they want is for me to go on this jag. They keep telling me I am at risk of overdose when I come 
out, but this is my recovery and I have worked really hard to come off this.” (E/BJ)
When prompted with, “how did the service respond?”, two participants spoke about speaking to staff 
at the addiction service and were given time and encouraged to keep engaging with staff:
“There have been one or two times (at risk of dropping out). The service was just curious as to why 
I felt like this.” (J/BJ)
“I have in the past (felt like dropping out) and I have felt like doing it this time because they think you 
are just a drug user. I have spoken to staff about this, they told me this is all in my head and that I just 
need to speak to them.” (M/BJ)
Some participants felt that they were less likely to drop out of treatment in prison than the community:
“The temptations aren’t the same as they are on the outside. I feel better able to control my drug use 
on the inside.” (8/BH)
“Not really in here but in the community definitely.” (G/B7)
“Not in here, but on the outside yeah.” (J/BJ)
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For another participant, medication was described as a “safety net” and both participants, below, 
identified MAT reducing harm from illicit drug use.
“It is a safety net and keeps me off the illegal drugs.” (D/BJ)
“No, there is nothing to lose for me. It either me asking for help or using.” (K/BJ)
Help available
When asked about what help was available to them, there was an acknowledgment that the 
pandemic has changed support options available:
“I am aware of the support that is there. I think there is some recovery places, but I don’t think they 
are on just now. I think things are different with Covid.” (M/13)
“With Covid going on there is not much happening. There is a number in the hall that you can phone.” 
(J/BM)
“I know there is support there but I don’t know much about it. I am not sure how much I need right 
now to be honest.    I have heard rumours there is a recovery cafe, but I don’t know if that is an option 
because of Covid.” (J/BK)
Some participants spoke about the pandemic increasing time spent in cells as missed opportunity to 
address issues while in prison:
“There should be places in the hall to support your drug use to give you a second chance especially 
if you are younger as you need to get people at a younger age before they are past this.  You are not 
meant to lock animals up, but you are left for 22 hours in a cell. There is no rehabilitation at all, and 
they wonder why you end up back in a few weeks later.  Life in jail sets you up for life of drugs.” (Q/
BQ)
“Because of this lockdown thing you don’t even get to see the doctor, it is only a phone call. You are 
lucky to get out of your cell.” (Q/AT)
Table 13 presents data on how safe participants feel to engage with addiction services. The majority, 
88% (N=14) felt safe to engage with addiction services in prison.
Table 13: Do you feel safe to engage with the addiction service in prison?
Do you feel safe to engage 





Not sure 1 6
Total 16 100
*Percentages have been rounded to the nearest whole number which may result in total adding to more than 100%
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Privacy and confidentiality was rated highly by participants. Having a relationship with staff was 
viewed as contributing to a positive environment by one participant:
“I know some of the staff now, so it is easier to get a bit of support.” (D/BH)
A recurring theme throughout the interviews was that participants felt they knew there was help 
available however there was a lack of clarity around the process of requesting help and the time 
delay for addiction staff to respond:
“It is just hard to get access as you need to fill in a form and that can take a couple of weeks and by 
the time, they get back to you, you can’t always be bothered.” (L/BM)
“No, you have to run to them and put a referral in and that can take weeks and by that point you 
can be past the stage that you referred for.  You are locked up for 21 hours a day because of Covid 
so things aren’t easy.” (M/BP)
“You get quite a lot of info, on poster boards although the wait to see someone can be lengthy.” (N/
AT)
“I don’t feel supported (now) that I am stable but there is no aftercare. I wouldn’t know how to 
contact my drug worker or prescriber. I would need to put in a form, and it would probably be picked 
up about 3 weeks later.” (J/BO)
“I am on remand and have been on remand for 7 months. I only tried to access additional support 
here the last few weeks as I felt too low when I came in to do so. I am still waiting.” (0/BR)
One participant suggested that having regular check ins from addiction team would increase their 
satisfaction with service:
“No, it’s like you are on your plan, you are on your meth.  You only get to speak to them when you 
ask, I think they should come to you.” (L/BP)
This was particularly an issue for participants knowing the process for accessing their prescriber with 
some participants unsure of who their prescriber is: 
“I don’t know who writes my prescription”. (G/B0)
“I never see my prescriber. I see my addiction nurse who I work with on my treatment plan.” (H/BO)
“It needs to be made easier to get access to your prescriber and your key worker, so you know what 
is happening with you script and to get help.” (G/BQ)
One participant shared their frustration at not having opportunities to discuss changes of medication 
dose with either their prescriber or worker:
“You need more than medication. You are allocated a worker, but you never see them unless you self-
refer and sometimes you don’t get to see them. Your dose just goes up or down they don’t contact 
you. If I hadn’t referred, I would just have kept using.” (M/AS)
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One participant’s experience of accessing support is that it is only available if requested both in the 
community and prison setting:
“If you chase help you get it both in the community and in prison. I only saw my keyworker in the 
community once over 12 months”. (G/AT)
Some participants valued the intermediary role that prison officers play in linking in people with 
addiction services as increasing satisfaction with their prison experience:
“Staff in the halls give you info and try and help you out by pointing you in the right direction and 
that.” (M/AT)
“They speak to you (prison officers), if you feel your mental health is going down you can refer 
yourself or get (prison) staff to speak to mental health support for you.” (R/AT)
Having time to build a relationship with your worker and feeling listened to were some of the key 
attributes of a good worker described by the following participants:
“Yeah, I do now as I work well with my worker but not at the start. My worker really wants me to help 
me turn my life around. Some nursing staff are just in it for the job. You need the right person”. (C/AT)
“Only because I have a good worker, but my worker is about to leave.    I didn’t really feel supported 
by my first worker. My worker genuinely listens and can see you are struggling. She doesn’t treat you 
like a stereotypical drug user”. (B/BP)
One participant suggested being able to access the drug service for support when you need it via the 
telephone in your cell would give access to support when you most need it:
“There is a new thing that you get a telephone in your cell and you can phone the Samaritans but 
you can’t access the drug service through this. It would be good if you could speak to someone about 
drugs.” (N/AU) 
Leaving Prison
Participants were asked if they know what will happen to their MAT on release from prison. Largely 
based on prior prison experience, participants did not seem duly concerned about their prescription 
being continued in the community:
“It hasn’t been discussed but because I am on remand, I know it will continue in the community.”
“It hasn’t been discussed yet. I have 4 months left so it will probably be discussed closer to my 
liberation date.” (R/BF)
“Not yet but I imagine it will be the same as any other time. You just go to the addiction service, and 
they will get you a chemist.” (J/BF)
One participant was concerned about continuing his MAT in the community if he were to be released 
straight from court:
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“I have discussed it with my worker as I asked what will happen.    I wanted to check what will happen 
if I get released from the court. They said I would have to access the drug service myself.” (C/BF)
Another participant expressed not knowing what will happen to his MAT on release and having no 
opportunity to speak to anyone about this:
“I have never spoken to a drug worker here, so I have no idea.    I was actually sitting wondering this 
the other day.  I think people are maybe given an appointment, but I am not sure.” (M/BF)
Naloxone
Overdose training and information was highly valued by participants although some expressed 
concern about the time it could take to get help:
“Going through overdose prevention. You go to a prison officer if you witness an overdose, and they 
get someone from the health centre. When you get released, they will put a Naloxone in my property. 
Some people are too scared to tell the prison officer regarding witnessing an over dose.” (C/AU)
“You can’t get Naloxone in the hall. You have to get an officer to get a nurse and that all takes time.” 
(E/AU)
You are trained in Naloxone but don’t have personal access to it so you have to ring a bell and it could 
take 20 mins for someone to come and speak to you and a further 30 mins to get to whoever needs 
help.   (There is) no access to nasal naloxone. (N/BQ)
One participant, who has been in prison multiple times, felt that the emphasis of Naloxone in prison 
increase the likelihood of you taking it on release. Although he still felt there was a stigma in the 
community to carrying Naloxone with you:
“They push Naloxone on you, which is a good thing as a lot of guys don’t bother with the health 
service. You stand a better chance of taking this with you when you leave because of this. Maybe 




This baseline study indicates why the implementation of the MAT standards are crucial to how 
people access and experience MAT within a prison setting. The experiential narrative gives insight 
into ways in which action can reduce both drug related harms and drug related deaths by increasing 
satisfaction with services with same day prescribing, choice of treatment and subsequent support. 
This snapshot illustrates some of the challenges of implementation within a prison environment. This 
prison baseline study aimed to be consistent with interviews already under way in the community. 
It demonstrated that the peer research model is transferable to a prison setting and should be an 
approach built into the planning stages of any future work into service user experience of the MAT 
standards. It highlights that fast access to treatment and ongoing support are issues for this cohort. In 
line with the community survey, this work was intended to shed light on the current living experience 
of people using services and in doing so provide a starting point to quality improvement in Perth 
prison. The challenge is in the how to move from where we are, to where the MAT standards require 
all services to be. This report suggests further work on implementation in prison should consider 
actions in the following areas as both specific challenges and opportunities for improvement. A 
caveat in the following is that 14 participants were on remand and more investigation is needed with 
individuals not currently on MAT as well as people serving a sentence.
Access
The process of accessing MAT for the first time in prison and continuation of MAT from community 
addiction services need to be made clearer to those requiring treatment. 
For people who are already in withdrawals in police custody, there needs to be an urgency to get 
people stabilised on treatment as quickly as possible. Participants acknowledged a frustration 
with time delay in recommencing treatment in prison at the appropriate level. There was a strong 
motivation to remain in treatment for this cohort.
For those not in treatment in the community when remanded there requires to be faster access to 
MAT. Of the four people not in treatment in community addiction services, they all waited more than 
two weeks from referral to starting treatment. In this time potential for drug harms increased as 
reported drug use increased. The wait to start MAT also impacted on motivation to change and was 
viewed by some participants to be a missed window of opportunity. The prison and NHS healthcare 
service need to consider how they proactively identify and engage with people who use substances 
to start treatment.
Prison officers and other prisoners were identified as a good source of information on services 
available in prison and consideration should be given to approaches that capitalise on this.
For people who had previous prison experience, it was acknowledged that waiting times to access 
appropriate MAT has improved but there was still improvements to be made.
Choice
Participants felt informed about prescribing options in terms of medication available.  There was less 
agreement with this sample around involvement in decision making around dosing. The importance 
of being able to access information in an accessible format was highlighted. For participants who 
continued their treatment from the community there was missed opportunities to review dose and 
engage in the process of MAT in a prison setting.
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For individuals not on treatment in the community better access and information on what is available 
to them is required.
Having adequate support is imperative to make informed choices and increase satisfaction with 
treatment services in prison. This sample suggests a varying degree of knowledge on what is available 
to make an informed choice.
Support
Extra support is required for people when waiting to start treatment and during the titration phase.
Access to support for mental health concerns need addressed as participants expressed limited 
opportunities to speak to someone.  Service development should also be clear on proactive 
engagement of individuals who may be reluctant to ask for help. Time and encouragement from 
staff to engage with treatment services were valued attributes. 
This study provides evidence that drop out from treatment in a prison environment is less likely than 
a community setting. There is a unique opportunity in prison to engage people and provide a quality 
of care which provides stability beyond prison.
The global pandemic has limited options of interventions available and increased time spent confined 
to cells.
The intermediary role of prison officers was viewed as key to linking with other services, this should 
be acknowledged and developed. People felt safe to engage with services on offer although the 
process of referral and delay in response results in appropriate help by the right people at the right 
time being missed. There was limited understanding of the roles of addiction worker and prescriber. 
Continuation of support on release from prison requires to be strengthened.
Potential time delay in administrating Naloxone was also highlighted as an area for improvement.
In line with the community survey, across the themes of access, choice and support, practice which 
is identified as disrupting delivery of MAT need to be eliminated if the MAT standards are to mark a 
watershed moment in reducing drug related harms and drug related deaths in Scotland.
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Appendice 4: MAT Participants information sheet
Medication Assisted Treatment - Current Practice in 6  Health Board 
Areas Across Scotland
Participant Information Sheet
Below is the participant information sheet for the Medication Assisted Treatment study of 
Current Practice in 6 Health Board Areas Across Scotland. You have been asked to take part in 
this.
Everything you say as part of this study will remain confidential.
The anonymous information you give about your experience of Medication Assisted Treatment will 
be used to define current practice and produce information that will inform the delivery of best 
care regarding medication assisted treatment. You can be assured that you will not be identified in 
any correspondence.
By agreeing to take part in this study you are agreeing that you fully understand what you are 
being asked to take part in, that you are fit and able to take part in a survey and that you give 
your full consent for your anonymous information to be used to support the study. Please speak 
with the peer researcher and ask any questions about this process that you may have.
 What is this study about? 
 Scottish Drugs Forum (SDF) want to find out more about your experience of receiving Medication 
Assisted Treatment (MAT). We want to find out what is working well and what is not, to find out if 
MAT is causing problems, and find if there are ways to fix problems or to stop them happening.
New standards of what to expect from MAT have been agreed by services and people with lived 
experience as part of the Drug Death Task Force to improve health outcomes for people who use 
drugs. Consultation on the implementation of the standards is under way. Your views, as part this 
study, will provide information to support the delivery of these standards.
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Volunteers who have a history of substance use will be conducting this study, these volunteers are 
the peer research team. SDF will be supporting the peer research team to run the study.
SDF will report back to Drug Death Task Force and to people who commission, deliver and work in 
services.
 What do I have to do to take part? 
After you have received this information sheet, we will ask if you want to take part in the study. We 
will call you, so it won’t use up your phone credit. We will then go over the information again so 
you can ask questions about taking part. After this we will ask if you want to continue. If yes, we will 
continue with the survey. You do not have to take part in the study if you don’t want to.
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During the phone call, the peer researcher will ask you a few questions, and the SDF team member 
will also be on the call to listen to your answers and answer any questions. The chat should take no 
more than 45 minutes.
If you like, we can send you the questions before the phone call, just ask the peer researcher. It’s fine
if you want to take a break or stop during the call, please just let the peer researcher know.
 What will you ask me about? 
We will ask you things like:
•	 Past and current experience of being prescribed either methadone or another opioid 
substitute.
•	 Access to treatment.
•	 Choice of treatment.
•	 Staff attitudes.
•	 Feeling safe in your service.
 Will things I say be confidential? 
We guarantee that the answers you give will be kept confidential. We won’t use your name and won’t 
give anybody information they could use to identify you. Your anonymity is guaranteed. Answers 
will be grouped together to give overall responses; for example, 79% of people stated We may use
quotes of what you said, but all quotes will be anonymous.
If you tell us that you or somebody else is at risk of being harmed, or that you are going to 
harm yourself, we will tell someone else to help. We will tell you before we do this.
The information you give will be stored anonymously in a MAT database and may be shared for 
the purpose of ongoing evaluation of MAT.
 Informed Consent 
We will ask you to give us verbal consent when the phone conversation starts. That means you are 
happy to take part in our survey. You can change your mind at any point during the survey. If you 
do change your mind, we will not use any of the interview.
When agreeing to take part in the survey, you are also allowing us to use your anonymous information 
to speak to health services or other people to inform the delivery of MAT. You are also giving 
permission for us to store your anonymous information in the MAT database with the potential for 
it to be used for other studies into MAT.
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Appendice 5: What to do if...
 





The person becomes 
upset or makes a 
request of support 
Inform person that you 
are going to call 
emergency services 
Note: A person becoming upset 
does not mean that they are 
unable to participate in data 
collection. But they should be 
offered the chance to stop data 
collection 
call emergency services 
If participant is at 
immediate risk of harm 
then follow relevant 
protocol - call 
emergency services 
Inform the participant 
that you will call back 
in ** minutes (number 
of minutes to be 
decided by UIDO). 
 
 
Signpost to services 
available in their area 
for support 
 
If participant is at 
immediate risk of harm 
then follow relevant 
protocol - call 
emergency services 
 
If they still do not 
answer, send text 
stating that you plan to 




opportunity for harm 
reduction infomration 








If they don't answer - 
try again immediately. 
If participant answers, 
then either arrange 
another safety call. Or 
Rearrange another 
interview time, if they 




Ask of they would still 
like to take part in the 
future 
 
If person is not at 
immediate risk but you 
have a concern of their 
ongoing welfare - set 






If concerned about 
immediate risk of harm 
- then follow relevant 




Signpost to services 
available in their area 
that can offer support 
 
Keep the participant on 
the call if possible - 





If not able to continue, 
cease data collection 
 
If happy to and has 
capacity to continue 
then complete data 
collection 
 
Either the UIDO or the 
peer researcher use 
the 'key word' so that 
each is aware that they 
are following this 
protocol 
 
You must cease data 
collection if you feel 
the person no longer 
has the capacity to 
offer ongoing consent 
 
You become concerned 
about a persons level 




The participant is at 
immediate risk of harm 
 
 
You become concerned 
about a participants 
welfare 
 
If not concerned about 
safety of participant 
then arrange to call 
back at another time 




Appendice 6: Prison questionnaire
Questionnaire Themes and questions
Section 1: Demographics – tell us a bit about you?
What age are you?
How would you describe your ethnicity?
How would you describe your gender? Male/other? 
Which local authority area you are from?
Is that the area where you hope to return to? 
What are you currently prescribed for MAT?
Section 2: Experience of treatment
How many times have you started a treatment plan or medication for your drug use? 
What is the longest time you have consistently spent on medication?
Were you in treatment immediately before entering prison?
- If yes, was this continued? Did your medication change when you entered prison?
-If no, had you tried to access treatment before entering prison? 
How long have you been on your current prescription?
What are your dispensing arrangements in prison? How does this work for you? 
What would you like your dispensing arrangements to be?
Section 3: Access to treatment
Did the prison service contact you with an offer of help to access the service or did you self- refer?
For your current prescription, how long did it take from you first making contact to get help 
before you started your medication?
What were things like for you before you accessed help?
90
What were things like for you when waiting to start your treatment plan?
What was the most important thing that helped you decide to take the offer of support at this time? 
Do you feel the process of accessing a treatment plan could be improved in any way?
Do you feel able to get help, support, and information that you need to keep safe and well?
What has been the most useful piece of harm reduction support/information you have received in 
prison?
Section 4: Choice of treatment
Did you have an idea of what you wanted when you first accessed services in prison?
- Yes, no, not sure -can you explain your answer? Were prescribing options discussed 
withyou?
Do you feel you had enough information to make an informed decision? 
Were dispensing arrangements discussed with you?
Was dose discussed with you?
To what extent do you feel the dose you started on was a shared decision?
If you are prescribed Buvidal, what are the pros/cons it has brought to your daily routine?
What will happen to your treatment plan when you leave prison? Has this been discussed with you?
Section 5: Retention/coping with crisis?
Have you had times on your medication that you felt in need of extra support? (what kind 
of support?)
Have you had times when you have been at risk of dropping out of the service?
- If yes, why was this and how did the service respond? Are you 
aware of support offered inprison?
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Section 6: Staff attitudes/feeling safe in service?
Do you feel safe to engage with addiction service in prison?
- Can you give some more detail on why you feel this way? Do you feel 
supported by your prescriber? Yes/no/notsure.
- Can you give more detail on why you feel thisway?
Do you feel supported by addiction staff in prison? Yes/no/not sure.
- Can you give some more detail on why you thinkthis?
Is there anything else that you would like to tell us in relation to you MAT?
Thank you for taking part in the survey.
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